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Abstract
The XXth World Congress of Psychiatric Genetics (WCPG), sponsored by The International
Society of Psychiatric Genetics (ISPG) took place in Hamburg, Germany on October 14-18, 2012.
Anderson-Schmidt et al. Page 2
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Approximately 600 participants gathered to discuss the latest findings in this rapidly advancing
field. The following report was written by student travel awardees. Each was assigned sessions as
rapporteurs. This manuscript represents topics covered in most, but not all, oral presentations
during the conference, and some of the major notable new findings reported at this 2012 WCPG.
Keywords
International Society of Psychiatric Genetics; World Congress of Psychiatric Genetics;
Sequencing; DNA; SCZ; PTSD; Substance Abuse; Pharmacogenomics
Introduction
The XX World Congress of Psychiatric Genetics, sponsored by The International Society of
Psychiatric Genetics took place October 14-18, 2012. Over 600 researchers gathered to
discuss the latest technological advances in the field and new findings about the genetics of
mental disorders.
The International Society of Psychiatric Genetics (ISPG) was first established as a non-
proifit corporation in the U.S.A. in 1992 and is a worldwide organization that strives for the
highest standards in the application of genetic methodologies to the study of psychiatric
disorders. It was formed to provide a stable structure for continual congresses in this field
with the mission of overseeing a rotating congress chairperson and program committee. This
year the congress was co-chaired by Markus M. Nöthen (Bonn, Germany) and Marcella
Rietschel (Mannheim, Germany). The following report represents topics covered during
most oral sessions at this conference and several of the major findings presented.
Rapporteurs for these sessions were student travel awardees who were assigned to
summarize individual sessions and their discussions. Similar accounts of the 2007, 2008,
2009, 2010 and 2011 congresses held in New York City, Osaka, Japan, San Diego,
California, Athens, Greece, and Washington, D.C. were previously published (Alkelai et al.
2008, Bergen et al., 2009, Amstadter et al., 2010, Bergen SE et al., 2011, and Dai N et al.,
2012.)
I. Plenary Sessions (reported by Olga Beltcheva, Geeta Thakur and Yash
Tiwari)
Professor Karl Zilles (Vogt Brain Research Institute, University of Düsseldorf) spoke on the
architecture of the human brain and began by stating that complete brain modeling requires
a multimodal approach from four important areas i.e. cytoarchitectonics- brain histology,
receptor architectonics- (Zilles and Amunts, 2009), Connectomics (Leergaard et al., 2012),
and functional architectonics The first key issue he raised was that the more than 100 years
old Brodmann brain map has drawbacks, as it lacks mapping information on 2/3rd of the
human cerebral cortex. The Brodmann model, did not study the intersubject variability of
the boundaries and size of cortical areas (Amunts et al., 2000; Zilles and Amunts, 2010).
Brodmann boundaries were observer-dependent and do not match more recent functional
and connectional MRI (Magnetic Resonance Imaging) studies, which are observer-
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independent (Amunts and Zilles, 2001; Caspers et al., 2012). This suggests a need for a
more modern approach to brain anatomy which is statistically testable in identifying
cytoarchitectural areas and mapping them to specific brain regions that could be transferred
to MRI.Prof. Zilles noted that JuBrain project (http://www.fz-juelich.de/inm/inm-1/EN/
Forschung/JuBrain/_node.html) is the research initiative to develop a three-dimensional,
realistic model of the human brain, focusing on continuous stereotaxic anatomical maps or
probability maps of cortical areas. Probability maps are superior to schematic maps and
currently available for more than 20 rat brains. Probability maps also helped to identify
FP1(Frontal Pole 1) and FP2 areas and the seven neocortical areas (Te 2.1–Te 7) of receptor
architecture, that have not been identified in the cytoarchitectonical map of Brodmann
(Zilles and Amunts, 2009). Work related to Three-dimensional maximum probability maps,
which are easier to understand, is in progress.
Professor Zilles then introduced the Human Brain Project (http://
www.humanbrainproject.eu/) which integrates their current knowledge of brain into
computer models, using these models to simulate the actual working of the brain. This work
involving full brain coverage at 20μm isotypic resolution is in progress. This project would
allow researchers to locate single cells, capillaries, and layers of cortex. It would be possible
to navigate and locate to any site of brain, compare its architecture, and reach far behind the
resolution of MRI scanner. By giving an example of hippocampus structure, he explained
why detailed cortical sub-divisions are essential for a meaningful anatomical and functional
interpretation. These could then be correlated with genome data in order to understand the
genetics of brain architectural variation.
The synchrony of different receptors in different brain regions decides brain function. An
example he gave is the AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor) distribution in primary motor cortex and hippocampus CA1-3 (Zilles et al.,
2004). Rceptor fingerprinting (Palomero-Gallagher et al., 2008) can be valuable for
computational models.
MRI technology has limitation in its resolution, for example in exAMINING 2μm thick
fibers. MRI also needs a lot of modeling and more modeling initially could provide more
complex results. He discussed his studies with fibre tracts and concluded that DTI
(Diffusion Tensor Imaging) and Connectomic studies are both supplementary and should not
be treated as a replacement for each other. He displayed a video analyzing a fiber tract with
ultra-high resolution polarized light imaging (PLI) in human striate cortex (Axer et al.,
2011), and projected to the level of myelinated fiber with clear resolution. In summary, he
noted that imaging began with a 1cm resolution and currently can reach up to a 1 μm
resolution, such that a single fibre can be seen, ultimately aiding in studying brain
connectivity.
Dr, Mark Daly (Massachusetts General Hospital) reviewed the genetic architecture of
psychiatric disorders and highlighted what he felt were the breakthroughs in genetic studies
of psychiatric disorders. During the ‘dark ages’, those in the field faced the paradox that
despite the clear heritable nature of these disorders, candidate gene and linkage studies were
failing to substantiate this, although a model of many genes with incomplete penetrance
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could easily explain this paradox. He identified the three key aspects of the recent successes
of psychiatric genetics; technology, collaboration, and genome resources. He discussed the
increased burden of Copy Number Variants (CNVs) in psychiatric disorders, and implicated
specific loci, many of which have since been associated with multiple psychiatric disorders.
However despite many regions with CNVs being identified, extracting genes and treatment
targets is a slow process.
In the search for common variants through genome wide association studies (GWAS),
unfruitful initial attempts led some researchers to conclude that common variants were not
the answer, and declared that rare variants were the way forward. The work of Shaun
Purcell, however, provided proof of a polygenic model for common variants (Purcell et al.,
2009). Similar to the CNV story, this suggested persisting with GWAS would ultimately
yield results. Through collaboration, in particular the Psychiatric GWAS Consortium (PGC),
substantial breakthroughs were made last year for SCZ (SCZ) (Ripke et al., 2011). Dr. Daly
presented a table he produced in 2011 of the number of hits per magnitude of sample size
increase for SCZ, comparing it to progress seen in other conditions, such as Crohn's disease
and height. Continued addition tripled the sample size of the PGC, bringing a further jump
forward that identified 62 genome-wide significant regions for SCZ and put it on a trajectory
similar to that of other complex traits. Other psychiatric disorders are still lagging behind in
sample size, so it remains to be seen if a similar number of associations will be found with
equivalent sample size increases in other disorders, particularly for childhood disorders.
He commented on the potential of next generation sequencing for understanding human
disease, but there are still difficulties facing studies of rare variants. In particular, the high
proportion of neutral variants complicates the detection of true disease effects. Current
studies for autism and SCZ are comparable to initial GWAS studies, with little deviating
from the null distribution. Extrapolating from the PGC GWAS, he stated that power is
greatly reduced at lower allele frequencies, citing that a common variant of small effect
(odds ratio (OR) = 1.2) is approximately equal to a rare variant (frequency 0.5%) with an
OR of 3. Finally, he briefly considered de novo mutations and presented observations from
an initial study of autism trios, stating that de novo mutations contribute little to overall
disease risk with only 10-20% of autism cases having a relevant de novo mutation. He
concluded by stating that despite GWAS explaining little of the disease variance, they will
yield substantial biological insights and emphasized the continual need for larger sample
sizes.
Dr. Bryan Roth (University of North Carolina Chapel Hill Medical School) discussed
“Novel Approaches to Psychiatric Drug Discovery”. As an introduction, he pointed out that
now, when the human genome is sequenced, we possess the tools to evaluate every possible
“druggable target” and receptors are among the best candidates. The Roth team has been
working on class A G-coupled protein receptors (GPCR), numbering approximately 300
members, which at present are targeted by only a small number of drugs. They have
developed and validated a highly automated pipeline, which allows them to perform parallel
screening of hundreds of targets. As an example of the possible applications for this
platform, Dr. Roth presented his on-going work on the hallucinogenic compound Salvinorin
A. They screened the drug against a large library of central nervous system molecular target
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and found that it is unique in having an absolute selectivity for a single target, the opioid
receptor (Roth et al. 2002). Determining the mode of interaction between ligand and
receptor became possible only after the structure of this GPCR was solved in collaboration
with Ray Stevens, The Scripps Research Institute (Thompson et al. 2012). It appears that
Salvinorin A binds the helical bundle of the receptor, engaging primarily non-conserved
residues. Since it is uncharged, it does not interact with a highly conserved aspartic acid
residue, found in all opioid and biogenic amine receptors, which is known to bind the
positively charged amine groups of the ligands. At present, Dr. Roth's team continues
working on the biochemical effects on the cell following the binding of the compound to the
opioid receptor. He concluded that the ultimate goal of psychiatric genetics is to have a
finding that will help the development of a cure, rather than just treatment of rare and
common diseases. There are several problems which need to be approached in order to
achieve that: first, the “single target problem”, where the disorder is due to rare catastrophic
mutation(s); second, the “multi-target problem”, where the disease results from multiple
variants each with modest effect; and third, the problem of those disorders for which there
are no known druggable targets.
As more human genomes are sequenced more catastrophic mutations will be found. Usually
they will affect only a limited number of individuals, so the most practical approach for drug
development would be to repurpose approved drugs, instead of developing completely novel
compounds. As an example for that approach Dr.Roth presented work on Angelman
syndrome – a neurodevelopmental disorder, resulting from inactivation of the gene for
ubiquitin protein ligase E3A (UBE3A) on the maternal chromosome in neurons (Huang et
al., 2011). They attempted to identify molecule(s), which could activate the healthy silenced
copy of the gene, using the automated pipline. Embryonic neuronal cell lines from knock-in
animals with a deletion of the maternal allele were screened using a library enriched in FDA
approved and EU approved drugs as well as drugs which have been used in human. One
compound, irinotecan – a topoisomerase inhibitor used for cancer treatment, managed to
unsilence UBE3A. Its in vivo testing is still underway. Using a similar approach Dr. Roth's
lab is currently working on other diseases, such as Rett and Prader-Willi syndromes. The
first results from these projects are expected within a year.
A completely different situation can be seen in the field of drug development for SCZ. To
this date the majority of compounds directed towards receptors involved in this disease have
turned out to be ineffective.It is highly possible that every future drug developed following
the current concepts would probably be unsuccessful because we are dealing with a complex
disease, which cannot be treated with a single target agent. In order to address that, his team
is currently working on the multi target design problem prospectively by creating drugs in
silico in collaboration with Andrew Hopkins, Dundeee University. Dr. Roth's team is also
trying to tackle the problem with SCZ drug discovery using the principle of functional
selectivity. They have based their work on the hypothesis that the single target drugs simply
bias the receptor by forcing it to adapt certain conformations. Thus, one could argue that for
example the canonical, G-protein mediated, GPCR pathway is responsible for the side
effects of these drugs, while signalling through the non-canonical, arrestin mediated
pathway, accounts for its therapeutic actions. Dr. Roth's team has tested the hypothesis by
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attempting to develop ligands of D2 dopamine receptors which affect only arrestin
signalling (Allen et al., 2011; Chen et al., 2012). The goal was to create a compound, which
was inactive on the canonical and highly active on the non-canonical pathway. They created
a library of synthetic analogues of aripiprazole, a well known and widely used antipsychotic
drug, with the help of a directed medicinal chemistry approach and tested them with the
parallel screening pipeline. They found three molecules, which have no activity on the
canonical G protein signalling, but are effectively blocking arrestin signalling. This ligand-
receptor effect has been confirmed in arrestin knock-out mice. The new compounds have
good pharmacokinetics and readily pass the blood-brain barrier. The initial data show that
they have no motoric side effect unlike other compounds used for treatment of SCZ. At
present the aripiprazole analogues have now advanced towards in vivo testing.
Dr. Peter Visscher (University of Queensland) spoke on “the missing heritability in
psychiatric genetics”. He briefly defined heritability as the proportion of phenotypic
variation that is due to genetic factors. It is a population-specific parameter that can be
estimated without knowing the information of individual genes. The estimation of
heritability depends on the scale of measurement. In a dichotomous disease risk scale,
heritability estimates are dependent on prevalence of disease. Alternatively, heritability can
be estimated via burden/ liability model, in which the risk of disease that is due to multiple
genetic and environmental factors can be expressed on a continuous scale. The burden/
liability models give predictions that are consistent with a) the observed recurrence risk of
relatives in SCZ in the McGue et al. (1983) & Lichtenstein et al. (2009) studies, suggesting a
strong additive genetic effect of disease risk; b) the idea that sporadic cases are normally
found in complex diseases as demonstrated in (Yang et al., 2010); and c) the high
discordance of heritability of liability observed in monozygotic twins due to the use of
simple models (Smith, 1970).
The estimated heritability of disorders can also be limited by the selection of a population.
For example, the heritability estimates of SCZ is 0.81 in a twin population (meta-analysis
performed by Sullivan et al. (2003) and 0.64 in the Swedish National study (Lichtenstein et
al., 2009). The combination of allele frequency and effect size of risk loci determines their
contribution to heritability of disorders. Data from the PGC1-SCZ study showed both the
extremely rare 22q11 deletion (effect size >20) and ZNF804A (effect size = 1.1, risk allele
frequency = 0.59) explain ∼0.1% variation in liability in SCZ. Variants with low frequency
(0.001 – 0.01) and intermediate penetrance (described by Sullivan et al.'s 2012 model of
genetic architecture) has remained underrepresented in current literature. The additional 62
SNPs identified from the PGC2 GWAS will hopefully fill in the gap of missing heritability.
It is known that siblings do not share exactly 50% genes from their parents due to
segregation and recombination of loci (heritability estimates = 0.31-0.64, SD = 0.04;
Visscher et al., 2006). In contrast to the misunderstanding that new variants introduce
missing heritability, Dr. Visscher pointed out that de novo variants arise across generations
and can potentially lead to the increase of heritability by 0.001-0.01%. More evidence is
expecting to emerge in the next few years. Other reasons such as chip design, statistical
power as well as interactions among the variants and environment can explain missing
heritability. Yang and colleague's study on human height has provided a direct estimation of
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missing heritability in GWAS (Yang et al., 2011). The variation of human height captured
by all common SNPs is 40-50% and it has now been referred to as ‘chip heritability’. In
SCZ, the ‘chip heritability’ ranges from 23-34% (Lee et al., 2012). The narrow sense of
heritability captured by GWAS is likely due to the absence of low frequency variants that
are not in linkage disequilibrium with the common SNPs. Dr. Visscher quoted “Essentially,
all models are wrong, but some are useful” from George E.P. Box (c.1919) to conclude his
talk. The liability composed of environmental factors, segregating and de novo variants will
explain phenotypic heterogeneity and the heritability of disorders.
This year, Dr. Raymond Crowe, Professor Emeritus from the University of Iowa, USA, was
awarded the Snow and Ming Tsuang Lifetime Achievement Award. In his talk, he journeyed
through his professional career path of nearly 45 years and reviewed how the field of
psychiatric genetics has evolved over the years, mentioning some key players at Iowa.
Although formally trained as a medical doctor, his genetic career began the day he met Dr.
Leonard Heston (Iowa City, USA) and was inspired by the adoption studies of SCZ, which
changed attitudes towards causation of mental illness. Dr Crowe's early career in the 1970s
started with his first publication in 1972 entitled “The Adopted Offspring of Women
Criminal Offenders” and “An Adoption Study of Antisocial Personality” in 1974.
Dr. Crowe shared memories of working at Iowa when there was no genotyping lab. In the
fall of 1984, he did the 1st DNA genotyping in the basement of the psychiatry department
and it took one week. Dr. Crowe is a pioneer in studies of panic disorder and published the
first linkage paper of panic disorder in 1987. Dr. Crowe also spoke about his involvement in
the “Iowa 500 study” where voluminous and extensive details were collected to make
diagnostic criteria which influenced the DSM. The “Iowa 500” was a majore contributer to
progress in psychiatric genetics as current studies of patients and families still employ the
methodology they introduced in the 1970s. He also mentioned the Collaborative Study on
the Genetics of Alcoholism (COGA) which was designed in the 1980s. Multiplex pedigrees
with alcoholism were collected and this study has stood the test of time with a design that is
still yielding good results today. Dr. Crowe quoted Charles Dickens saying: “It was the best
of time; it was the worst of times”. He was reminiscent of how many things have been
learned about psychiatric disorders over the years, such as how diseases are being
transmitted, about the polygenic model and notion of complex inheritance, and how the field
of psychiatric genetics has so many layers of complexity. He concluded with a modified
quote from his own medical doctor: “Half of what we believe is wrong and the other half of
what we know is not what we would expect”.
II: Affective and Anxiety Disorders (reported by Enda Byrne, Nathaniel
McGregor and Alessio Squassina)
A. Bipolar Disorder (BP)
Dr. Elaine Green (Cardiff University, UK) reported on findings from the genotyping of
2,106 SNPs, selected from the Ferreira et al. (2008) meta-analysis in a sample of 1,218 BD
patients and 2,913 healthy controls. CACNA1C and ODZ4 genes as well as region 15q14
were replicated, but not the ANK3 gene. Two significant SNPs were located in regions not
Anderson-Schmidt et al. Page 8
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
previously associated with BD (12q13.1 and an intronic SNP in the TRPC4AP gene, Ch.
20q11.2).
Dr. George Kirov (Cardiff University, UK) discussed new data from a study on de novo
CNVs carried out on a sample of 282 BD and 76 SCZ families. Thirteen CNVs were
identified in 302 BD offspring (4.3% rate) and 6 in the SCZ sample (rate 7.9%). These rates
were significantly higher than in healthy controls (rate 1-2%). The median size of de novo
CNVs was 160Kb in BD and 640Kb in SZ.
Dr. Nirmala Akula (NIMH, USA) presented findings from the first RNA sequencing study
in BD performed postmortem on dorsolateral prefrontal cortex from two different samples
comprising 11 BD subjects and 11 controls. PROM1, ABCG2, A2M and FLI1 genes as well
as the long non-coding RNA, LINC00173, were dysregulated in BD. Of the several GO
categories functionally enriched, “ion binding” and “neuronal development” were also
enriched for GWAS signals. Many genes were replicated by microarrays in an independent
sample of 22 cases and 26 controls.
Dr. Stéphane Jamain (Inserm, France) resequenced the promoter and regulatory regions of
the ASMT gene (involved in melatonin metabolism) in 345 BD patients and 220 controls
(Etain et al., 2012) identifying 8 rare variants associated with BD and reduced enzymatic
activity. A common variant (SNP rs4446909) was also associated with BD and with lower
mRNA level and enzymatic activity. Findings were replicated in an independent cohort (480
BD patients and 672 controls) and in the combination of both datasets.
Dr. Thomas Schulze (University of Göttingen, Germany) spoke on behalf of Dr. Rene
Breuer (Central Institute of Mental Health, Germany). Using a market research tool
(association rule mining), the study searched for associations between genotypes of SNPs
selected from a previously published GWAS on BD (McMahon et al., 2010) and multiple
phenotypes in a sample of 2835 BD patients and 2744 controls (comprising a discovery and
a replication sample). One multilocus genotype pattern was associated with comorbid eating
disorders (combined p=4.937e-14, OR=4.1) and another one was associated with simple
phobia (combined p=1.686e-11, OR=3.2).
Dr. Pamela Sklar (Mount Sinai School of Medicine, USA) presented findings from a PGC-
BD GWAS study on 25.000 subjects performed by using different platforms for detecting
both rare and common variants. Analyses revealed a number of significant SNPs located in
CACNA1C, ODZ4, CAPN10, TRANK1, LMAN2L and VIPR2 genes. Some of these genes
were previously implicated in BD by GWAS while others are correlated with pathways
previously involved.
B. Depression
Dr. Elisabeth Binder emphasized the role of environment in depression, the need to increase
focus on the environment, and the need for better identification of relevant environmental
variables. She highlighted that biological systems that mediate response to the environment
could be important and that the stress hormone system is known to be disrupted in stress-
related disorders. A key molecule for regulating stress response is the glucocorticoid
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receptor. A cohort of 160 males were treated with a glucocorticoid-receptor agonist and their
gene expression was measured prior to treatment and 3 hours later. QTLs that were
associated with altered gene expression were identified. SNPs were enriched in
glucocorticoid response elements and glucocorticoid receptor-associated transcription
factors. Furthermore, these SNPs show more evidence of association with Major Depressive
Disorder (MDD) than random selections of SNPs. There was some evidence that the QTLs
acted by altering long-range chromatin interactions. This study provided direct evidence for
a gene × environment interaction at the molecular biological level.
Dr. Robert Power (Kings College London) presented a study on the evolutionary
consequences of depression alleles on fitness. Fitness was measured by fecundity. Prior
evidence suggests that there is no decrease in fecundity in MDD cases and siblings of cases
have more children on average. Using data from the Swedish population registry, genetic
profile scores were constructed for >2,500 individuals using the results from the Psychiatric
Genomics Consortium MDD GWAS, and regressed on the number of grandchildren each
individual had. An inverted u-shaped distribution was found, with those carrying an average
number of depression alleles found to have the most grandchildren, and those carrying either
more depression alleles or fewer depression alleles than average had fewer grandchildren. A
study on the effects of inbreeding on depression risk was presented. Using data from the
PGC MDD study, runs of homozygosity were identified and a test for excess of runs of
homozygosity was performed. No consistent pattern was found between cohorts.
Dr. Sarah Mostafaci (Stanford University) presented a study that combined pathways and
RNA-sequencing expression data to unravel the functional units that contribute to MDD.
Analysis of gene expression patterns found in cases and not in controls may help to identify
biological markers that are informative of the pathophysiology of MDD. Gene expression
was measured in 459 recurrent cases and 463 controls. The participants had also been
genotyped on a GWAS chip. After extensive QC, QTLs were identified and gene-wise
statistics were computed. Two significant pathways were identified. These pathways were
related to cell migration through the cytoskeleton and cell adhesion respectively. All QTLs
for genes in the significant pathways were identified and tested for association with MDD. 9
SNPs were significant
Dr. Gerome Breen (King's College London) highlighted the lack of significant findings in
GWAS studies of MDD. This could be due to many factors, foremost amongst them, the
need for larger sample sizes. He presented data showing that a GWS significant hit had been
identified in an analysis of late-onset depression, but replication has not yet been attempted.
Furthermore, he highlighted that early-onset recurrent depression had a higher heritability
and that focusing on depression subtypes may be informative. CNVs have not been widely
investigated in MDD, but there is evidence for an excess of exonic deletions in cases
compared to controls. Epigenetics is another area that offers promise for future
investigations of MDD.
Dr.Cathryn Lewis (King's College London, UK) discussed the failure of genome-wide
association studies to identify replicable risk alleles for major depressive disorder (MDD).
She indicated that her group believes that heterogeneity may be providing sufficient noise to
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reduce power, preventing association from being detected, but that looking at age at onset
(AAO) in the PGC-MDD data could reduce some of the heterogenic noise observed. She
discussed her approach of using octiles of AAO distribution within each study, due to an
assumption that heterogeneity around AAO was a result of study-specific differences and
not differences in depression cases. AAO was found to differ significantly by study with
medians ranging from 20 to 37 years of age. The majority of depression cases were found to
be below 40 years of age. With this strategy one single nucleotide polymorphism (SNP) was
found to be in full genome-wide association in the PGC-MDD cohort and a number of other
SNPs showed ‘suggestive significance’. Dr.Lewis showed that AAO can be considered a
usual covariate tool for reducing the heterogeneity of depression in the analysis of data
across studies, although this still proves to be challenging due to cross-study differences.
Karen Hodgson (King's College London, UK) discussed genetic predictors of antidepressant
side effects. In order to assess which patients are at greater risk for developing a particular
drug-related side-effect, adverse drug reactions were categorised into one of four groupings,
namely adrenergic, cholinergic, serotonergic, and histaminergic. A patient cohort ranging
from moderately to severely depressed patients was used with the drug focus being
escitalopram (an SSRI) and nortriptyline (a TCA). Genetic prediction association was found
only for the serotonergic group, namely rs6644093 (P = 7.43 × 10-5) in HTR-2C. No
significant association was found in the remaining three adverse reactions groupings, but
this was postulated to be due to reduced power as a result of low sample numbers within
drug-specific groupings.
C. Anxiety Disorders
A common underlying diathesis amongst anxiety disorders was presented by Dr. John
Hettema (Virginia Commonwealth University, USA). He presented work pertaining to the
integration of data across multiple anxiety disorders for input into GWAS to find possible
common underlying associations. Target cohorts for analysis comprised panic disorder,
generalized anxiety disorder and several phobic disorder categories for six European
ancestry samples totalling 24000 individuals. GWAS meta-analysis showed nominal
association for several prior candidate genes but further analysis is still currently underway.
TMEM132D had been implicated by many an independent study in the pathogenesis of
anxiety disorder. Last year Erhardt and colleagues identified TMEM132D as a potential
candidate gene for panic disorder (Erhardt et al., 2011). Dr. Angelika Erhardt (Max-Planck
Institute, Germany) spoke about methylation patterns within the TMEM132D gene.
Professor Erhardt looked at 116 CpG sites in DNA extracted from peripheral blood in
traumatised individuals from the inner city of Atlanta. She found no associated between
panic risk variants and TMEM132D methylation but did find association between
methylation patterns and PSS scores for anxiety. She also alluded to a lower pattern of
methylation being associated with post-traumatic stress disorder (PTSD).
Dr Martin Kohli studied repeat expansions within the C9ORF72 gene and its contribution
towards Alzheimer's disease (AZ). Dr Kohli's presented findings alluded that the expansion
repeat in C90RF72 (>30 expansions) can contribute to the pathogenicity of AZ, in addition
to its current association with frontotemporal dementia (FTD) and amyotrophic lateral
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sclerosis (ALS). The repeat is also less frequent in African than European Americans, and
this points to differences in ancestral haplotype frequencies, including haplotypes at
potentially different risks for repeat expansion.
III: Schizophrenia (SCZ; reported by Mark Z. Kos, Sandra Meier and Heike Anderson-
Schmidt)
Yi Lin (University College, London, UK) studied missense mutations in CACNG5 and its
association with SCZ and Bipolar disorder. She discussed her work which aimed to identify
disease relevant genetic variation in the calcium channel gene CACNG5 and study it's
possibly biological implications in vitro. Yi found an association of the rs17645023 marker
in a case vs. case analysis (P = 6.3 × 10-7) and also in a combined analysis of 8 non-
synonymous SNPs in the CACNG5 gene in SCZ and Bipolar patients vs. controls (P =
0.00082), bringing the session to a very positive close.
Dr. Aiden Corvin (Trinity College Dublin, Ireland) investigated whether Protein-Activated
Kinase 7 (PAK7) duplications in an Irish sample of SCZ patients, were generalisable to
other psychotic disorders (bipolar disorder) and whether this represented a rare regional
duplication. PAK7 duplications were found to be more generally associated with psychosis
and not just SCZ. However, this particular duplication appears to be more frequent in
Ireland and the UK, suggesting a common ancestral mutated event. Close relatedness within
the samples was tested and eliminated as a possibile explanation for these results. PAK7
mutations have clinincal implications as the majority (12 out of 13) of mutation carriers had
a chronic course of illness and poor outcome. The exact genetic mechanisms of PAK7 are
yet to be determined. However, similar to DISC1, this gene appears to be involved in
dentritic spine regulation Brandon and Sawa 2011. It was discussed that this mutation might
also be present in underpowered samples of other European ancestries.
Dr. Linh Duong (Institute of Biological Psychiatry, Copenhagen University Hospital,
Roskilde, Denmark) presented a detailed genetic analysis of two patients and their families
on the Neuroxin1-Gene (NRXN1) to investigate possible gene-specific psychopathological
phenotypes. NRXN1 has previously been implicated in SCZ, autism spectrum disorders and
intellectual disability Shah et al. 2010. Both patients had early onsets of mental difficulties
and low social functioning. Patient 1 was diagnosed with autism, mental retardation, and
epilepsy whereas patient 2 fulfilled the criteria for SCZ. Genotyping revealed that patient 1
carried a large CNV deletion (451 kb), in addition to a point mutation. Patient 1 showed a
family history of autism (maternally) and SCZ (paternally). In contrast, patient 2 had two
closely linked small CNVs and while there was some family history (schizophreniform
disorder, depression), not all mutation carriers were affected. Dr. Duong's study Duong et al,
2012 illustrates the diverse clinical manifestations (type and severity) resulting from
NRXN1 mutations, implying pleiotropy and incomplete penetrance in NRXN1. The severity
of the disease was not correlated with any one mutation.
Ms de Candia (University of Colorado, Boulder, USA) investigated whether specific SNPs,
linked with SCZ, are shared across populations or are population-specific. To date, most
genetic analyses are carried out on people of European descent. Few direct comparisons
between SCZ patients of different ethnicities exist. De Candia examined the extent to which
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additive genetic variance in susceptibility to SCZ is shared by people of European American
(EA) and African American (AA). A genotypic similarity score was computed based on an
established method Yang et al. 2012. Controlling for confounds, it was found that common
SNPs predict a large proportion of the genetic variance in both populations. While there was
evidence for shared genetic variance, the samples were not pure but consisted of mixed
populations particularly within the AA group. In addition, environmental effects were not
taken into consideration.
Dr. Ruderfer (Mount Sinai School of Medicine, New York, NY, USA) examined the role
rare recessive heterozygote variants play in SCZ based on the rationale that for every 1 %
increase in autozygosity the odds of developing SCZ increase by 17 % Keller et al. 2011. It
was found that patients with SCZ did not show a significant increase in rare loss of function
(LOF) variants of any particular gene. Runs of homozygosity (ROH) suggest autozygous
regions that are enriched for recessive mutations. However, no different rates were found for
cases and controls.
Dr. O'Dushlaine (The Broad Institute, Cambridge, USA) used the lobSTR algorithm
Gymrek et al. 2012 to assess tandem repeat variations in 5000 SCZ exomes in a Swedish
sample. This was based on the rationale that no comprehensive survey of exome repeat
variations in SCZ had been carried out to date. Contrary to expectations, no evidence was
found for an overall significantly increased burden of repeat variations in cases compared to
controls. However, specific local variants were enriched in patients with SCZ highlighting
potential new candidates for SCZ susceptibility. Various different small and non-
frameshifting events at these loci might thus increase the risk for SCZ.
Dr. Degenhardt (Institute of Human Genetics, University of Bonn, Germany), presented her
results based on an analysis of CNVs in genes that have previously been reported to carry de
novo mutations in SCZ (Girard et al. 2011; Xu et al. 2011). 55 candidate genes were
therefore screened for CNVs in populations of cases (SCZ and schizoaffective) and controls.
Higher rates of RB1CC1 duplications were found in 7500 patients with SCZ compared to
112 000 controls, illustrating the success of a candidate gene approach. RB1CC1 has
previously been found in children with intellectual disability (Cooper et al. 2011) and
appears to be related to cognitive impairments.
Dr Colm O'Dushlaine (Stanley Center for Psychiatric Research, Broad Institute of MIT and
Harvard, Boston, MA, USA) presented the results from a large genome-wide association
study (GWAS) combining the data of the 1. wave of the PGC workgroup SCZ with a
Swedish sample. The Swedish cohort was ascertained via electronic hospital records, all
patients were assigned a clinical diagnosis of SCZ and both of their parents were of Swedish
ancestry. In sum the Swedish sample included 5351 cases and 6509 control subjects. The
sample was very homogeneous, only a few Finnish outliers could be observed in
multidimensional scaling plots. 6% of the variance in the Swedish was explained by the
polygenic score of PGC 1.wave sample. The GWAS revealed novel genome-wide
significant associations at C2orf69 and SNX19. 154 of 201 SNPs displayed the same
direction of effect in the Swedish cohort as in the PGC 1.wave sample (sign test p= 8 ×
Anderson-Schmidt et al. Page 13
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
10-15). Additionally, the results increased the evidence for a MIR137 association and
deletions at 9q21.11 and 22q11.21, as well as duplications at 16p11.2, 11p11.21 and 7q36.1.
Dr Stephan Ripke (Center for Human Genetic Research, Broad Institute of MIT and
Harvard, Boston, MA, USA) reported the results of a GWAS including the data of the
1.wave of the PGC SCZ and bipolar disorder workgroups. Genome-wide significant was
observed at PIK3C2A and ELTD1. Dr Ripke noted the problem of overlapping control
samples and matching procedure for bipolar and SCZ patients. Surprisingly no locus
surpassed the threshold of genome-wide significance in the comparison of these two
phenotypes. Additionally the polygenic score of PGC 1.wave bipolar sample significantly
predicted the mania subphenotype of SCZ (p=0.005), but not those of depression, negative
and positive symptoms.
Dr Robert Power (Social, Genetic and Developmental Psychiatry Centre, Institute of
Psychiatry, London, UK) discussed the false discovery rate (FDR) procedure. This is
designed to control the expected proportion of incorrectly rejected null hypotheses. He
suggested that the FDR performs better in finding non-null SNPs. Further he proposed that a
FDR procedure conditioned on comorbidities in SCZ would lead to smaller FDR values for
a given effect size, which might empower analyses.
Dr Anders BØrglum reported on a GWAS of 915 SCZ patients and 915 matched control
subjects, with initial results followed up in Danish, German and Dutch samples. No marker
surpassed the threshold of genome-wide significance (best p-values at RUNDC2A (p=9.04 ×
10-7) and CDH13 (1.2 × 10-6)), region-based analysis revealed a significant association of
ZEB1, which was successfully replicated. ZEB1 is regulated by TCF4 and is involved in the
regulation of CDH13. Dr BØrglum further presented the results from a genome-wide
interaction analysis, which revealed that genetic variation at CTNNA3 in interaction with
maternal cytomegalovirus infection increased susceptibility to SCZ.
Dr Giulio Genovese (Stanley Center for Psychiatric Research, Broad Institute of MIT and
Harvard, Boston, MA, USA) refered to missing pieces of the human genome (megabase
pairs of euchromatic human genome sequence that have no home on the reference human
genome assembly). He described an approach for localizing these missing pieces utilizing
the patterns of genome sequence variation created by population admixture. He observed
that most of the hereby identified sequences were hidden in the genome's heterochromatic
regions. One region harboring such missing pieces is the 1q21.1 region. The 1q21.1
microdeletion has been reported to be associated with several clinical phenotypes. Several
localized missing pieces mapped to the distal part of 1q21.1 and HYDIN2.
Dr Benjamin Neale (Stanley Center for Psychiatric Research, Broad Institute of MIT and
Harvard, Boston, MA, USA) eported on a recent exome sequencing study of 13,000
individuals from the Swedish SCZ cohort, of these subjects 9,000 were clearly of European
ancestry, 2,000 of African and 500 of Asian/Hispanic Ancestry. 1,107,051 nonsynonymous,
44,529 splice variants and 31,003 stop gain/loss variants were analysed with the Exome
Chip. This chip further includes GWAS Tag SNPs, SNPs covering the HLA system and
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some common variants enabling to infer population stratification. The analyses of the rare
variants resulted in no genome-wide significant association.
Dr. Ann Collins (University of North Carolina, Chapel Hill, NC, USA), discussed the
potential role of MIR137 (microRNA 137), a known regulator of neuronal development
(Silber et al., 2008; Smrt et al. 2010; Szulwach et al., 2010) implicated in SCZ risk by
PGC-1 (Ripke et al., 2011). Focusing on an extensive linkage disequilibrium (LD) block
comprised of top GWAS hits, the authors identified a haplotype with a significant,
protective effect.
Dr. James Walters (Cardiff University, Cardiff, UK), presented the clinical and genetic
validation of a new SCZ sample (CLOZUK;n = 6,268), collected anonymously from blood
stored by the UK Human Tissue Authority and receiving treatment with clozapine, an
antipsychotic for treatment-resistant SCZ. This unconventional sample was clinically
validated, producing a positive predictive value (PPV) of 88% for narrow SCZ. Genetically,
CLOZUK compares favorably with the PGC-1 findings, with 47% of the top PGC-1 hits (n
= 81) showing nominally significant association in CLOZUK.
Dr. Olli Pietiläinen (Wellcome Trust Sanger Institute, Cambridge, UK) presented results of a
genetic investigation of a Finnish population isolate with a high incidence of SCZ. Scanning
their sample (n = 173) for deletions greater than 20 kb, they identified a rare, yet
significantly enriched, deletion at 22q11.22. This deletion shows significant association with
SCZ within the isolate (P = 0.031), as well as more broadly in the Finnish population (P =
0.0065), and appears to down-regulate the gene TOP3B.
Alex Richards (Cardiff University, Cardiff, UK). Spoke on the CLOZUK cohort, along with
475 Welsh samples with cognitive data. These were genotyped and tested for association
with SCZ and cognitive performance. With the exception of MHC variants, none of the
SNPs (n ∼ 200,000) exhibited genome-wide significance. When meta-analyzed with the
PGC-1 (Ripke et al., 2011), a number of top hits were successfully replicated, along with
four new SNPs that attained genome-wide significance.
Eilis Hannon (Cardiff University, Cardiff, UK), discussed her group's analysis of gene
expression patterns in fetal brains and their relationship to GWAS data for SCZ and bipolar
disorder (BP). Using global transcriptome data for 13 brain regions from two independent
studies (Johnson et al., 2009; Kang et al., 2011), they found genes with consistent
expression across the mid-fetal brain to be enriched in both disorders.
Dr. Stephan Ripke (Center for Human Genetic Research and the Broad Institute, Boston,
Massachusetts, USA and the Psychiatric GWAS Consortium, PGC) spoke about the PGC,
which is an international group of researchers aiming to maximize the utility of extant
psychiatric GWAS through mega-analysis. Previously having identified multiple loci
involved in SCZ using 20,000 individuals (Ripke et al., 2011), Dr. Ripke sought to increase
the sample size to 25,000 cases and 28,000 controls for a collaborative analysis that includes
samples from the UK, Sweden and USA. This new combined meta-analysis has identified
62 SNPs with genome-wide significance in SCZ. Dr. Ripke reasoned that there may be an
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upper limit to the number of genes affected in this disorder. However, based on Polygene
Modeling, he believes that a plateau has not yet been reached.
Dr. Menachem Fromer (Mount Sinai School of Medicine, New York, USA) reported on the
role of integrating genetic variation with protein annotations in SCZ sequencing. He
discussed whether protein domains might play a role in coding genetic variation, and
whether this genetic variation contributes to disease risk. Dr. Fromer used exome
sequencing from the 600 trios project from Bulgaria and from 2,500 cases and 2,500
controls in a study from Sweden using a combination of exome capture arrays, and applied
InterProScan to annotate RefSeq gene transcripts with the location of their functional protein
signatures. Dr. Fromer also used Similarity Matrix of Proteins (SIMAP) (Rattei et al., 2010)
to predict protein function and analysed the data using PLINK/SEQ software. Analysis of
variants will focus on de novo (rare) mutations including single nucleotide variants (SNVs),
indels and copy number variants (CNVs) (Fromer et al., 2012).
Dr. Panos Roussos (Mount Sinai School of Medicine, New York, USA) reported on gene
coexpression networks, or integrative “omics”, to examine gene networks for their
enrichment for SCZ associated genetic risk variants. Transcriptome profiling of human post-
mortem non-disease samples was used to explore modules of genes that may be risk factors
for SCZ. Initially, an expression quantitative trait loci (eQTL) analysis was completed to
examine whether common SCZ GWAS risk variants are enriched for eQTLs (Roussos et al.,
2012). Dr. Roussos also compiled a list of large risk factor CNVs from the literature and
used de novo missense, nonsense and splice site mutations obtained from exome sequencing.
Using integrative “omics”, he examined whether there was a gain or loss in the module
connectivity in SCZ using two independent microarray datasets. Forty-six modules
(52-1,792 nodes) were detected. He found that GWAS SCZ risk modules were enriched for
genetic risk variants (eQTL, de novo mutations and CNVs) that disturbed critical hub genes
in the modules.
IV: Autism
Dr.Scott Selleck (Pennsylvania State University, USA) discussed findings from assessing
CNV burden in Autism Spectrum Disorder (ASD) cases. Using individuals from the
Childhood Autism Risks from the Genetics and Environment (CHARGE) study (Hertz-
Picciotto et al., 2006), the authors examined CNV burden in 107 genomic regions flanked by
segmental duplications (genomic hotspots) as well as other rearrangement-prone areas. They
found significantly more base pair duplications in ASD individuals vs. controls, similar to
previous work (Girirajan et al., 2011). There was an increase in duplication burden in five
specific hotspots. The results suggest a mechanistic bias toward duplications in the etiology
of ASD.
Holly Cukier (Hussman Institute for Human Genetics, University of Miami, USA) presented
findings from work related to exome sequencing in a large extended families which contain
at least one pair of affected cousins. The authors hypothesized that dominant, partially
penetrant variants would segregate with the pedigrees. By combining their exome data with
available identity by decent (IBD) information, the authors were able to drastically filter
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potential regions harbouring potential ASD related-variants. They identified mostly
dominant changes, with some recessive and X-linked. They found 112 candidate genes in
IBD regions. The genes identified included 13 known ASD gene and approximately a dozen
novels genes, several recurrent in families. The authors conclude that use of IBD regions is
robust for filtering, and can identify both novel and known diseases genes.
Anthony J. Griswold (Hussman Institute for Human Genetics, University of Miami, USA)
presented research related to use of target sequencing of regions identified in ASD by
GWAS. Dr. Griswold argued that targeted can be more effective than exome sequencing for
identifying disease genes in genomic regions of interest. Using 919 unrelated cases with
ASD and 854 controls, they targeted 689 genes plus 5kb from their transcriptional starts and
ends, conserved regions within non-genic haplotype blocks and entire haplotype blocks. Out
of a total of 603,124 identified single nucleotide variants (SNVs) across all individuals,
48,891 (8.1%) occurred within exons or at splice junctions of one of the targeted genes,
15,099 (2.5%) induced nonsynonymous amino acid changes, and 8,829 (1.5%) were
predicted to induce a damaging amino acid change. In the future, they plan to look at non-
coding and intergenic variants as well as increasing sample size.
Christine M. Freitag (Goethe-University, Frankfurt, Germany) presented work related
Cntnap2, a well-studied candidate gene in ASD. Cntnap2 has appeared in many linkage,
CNV and association studies (Penagarikano and Geschwind, 2012). It is expressed in ASD
relevant brain regions related to speech, it also interacts with FOXP2. Thus far, no studies
have examined promoter variants of Cntnap2. The authors hypothesized that promoter
variants would be associated with ASD, that they would affect gene expression, and that
they would influence language development. Using direct sequencing of 200 families, they
identified three of the ten annotated SNPs in the region, and seven novel SNPs in there
sample group. There was a nominal association of the SNP rs34712024 and the short tandem
repeat (STR) rs71781329 with ASD. The SNP rs150447075 was nominally associated with
age of first sentence in months. rs34712024 and rs71781329 but not rs150447075 showed
significant increases (∼ 1.7 fold) in Cntnap2 promoter function. All three variants localize
to the binding site of the transcriptional repressor Neuron Restrictive Silencer Factor
(NRSF) and its cofactor SYN3A. The authors propose that variation in the transcription
factor binding site of NRSF and SYN3A act as a protective factor by altering expression of
Cntnap2.
Andreas Chiocchetti (Goethe-University, Frankfurt, Germany) presented research related to
the role of a rare Rpl10 mutation in ASD. This group found two missense mutations in exon
7 of the ribosomal protein Rpl10 in a mutational screen of families with ASD. Further, these
mutations alter the translational capacity of the ribosome (Chiocchetti et al., 2011; Klauck et
al., 2006).These authors sought to find which pathways are affected by the specific
mutations and if any overlap with other disorders. Using lymphoblasts, they screened for
proteins with altered overall expression and change in abundance between individuals
harbouring the mutation vs. controls. Alterations were found in protein isoforms relevant for
glucogenesis, oxidative stress and mRNA. It appears that Rpl10 deficiency mimics oxidative
stress.
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Dr. Derek Morris (Trinity College, Dublin, Ireland) presented results of next-generation
sequencing of the exonic regions of 215 putative susceptibility genes in 151 Irish cases of
ASD, 273 of SCZ and 287 controls. The authors sought to identify rare mutations
contributing to one or both disorders, given the similar phenotype and underling genetics of
the two disorders. They found that 29 of the cases carried loss of function (LoF) variants. A
de novo nonsense variant was found in Grin2B as well as LoF variants in neurexin in nine
cases. This research furthers the evidence for association of these genes with ASD and SCZ.
V. Other Childhood Psychiatric Disorders (reported by Katri Kantojärvi)
Dr Cynthia Bulik (University of North Carolina at Chapel Hill) presented GWAS results on
anorexia nervosa (AN). AN is a debilitating and potentially lethal mental illness (prevalence
∼1 in women; sex ratio ∼9:1; heritability estimates 22-88). This collaboration between The
Genetic Consortium for Anorexia Nervosa (GCAN) and Wellcome Trust Case Control
consortium (WTCCC3) conducted the largest GWA in AN thus far. Genotyping was
completed on 2,907 AN cases and 14,860 controls. Controls were carefully selected to
match cases geographically. No SNPs reached genome-wide significance in the discovery
analysis nor in a meta-analysis of the discovery and European replication datasets
comprising a total of 4883 cases and 20653 controls. A sign test with an independent
WTCCC3 anorexia replication sample (1,860 cases) revealed 80% of SNPS were in the
same direction as the discovery meta-analysis (binomial p-value 0.000001). Additional
collection of AN cases are planned.
Dr Christel Middeldorp (Biological Psychology, Vrije Universiteit) discussed a genome
wide meta-analysis of internalizing problems at age 3. Internalizing problems which are
highly heritable were assessed with the internalizing problem subscale of the Child Behavior
Check List (CBCL). GWAS data were available for 1,594 twins from the Netherlands Twin
Register (NTR), 2,037 Dutch unrelated individuals from Generation R (GenR) and 1,084
individuals from Raine, Australia. Methods used in analyses were PLINK, METAL,
VEGAS and Ingenuity. No single SNP reached genome wide significance. The most
promising results appeared on chromosome 9q33.1 in an intergenic region and on
chromosome 20p12.1 at the PCSK2 gene with several SNPs having a p-value below 1*10-4.
Genes associated with adult psychiatric symptoms appeared to be associated with
internalizing problems at age 3.
Dr Iiris Hovatta (University of Helsinki) presented her study which investigated if childhood
adversities affect adult age leukocyte telomere length of the Finnish population. Several
recent studies, but not all, have shown that childhood stress is associated with shorter
Leukocyte telomere length (LTL) later in life. However, it is unknown whether childhood
stress and consequently shorter LTL are important on a population level. This study
hypothesized that the number of childhood adverse life events predicts shorter LTL at adult
age and investigated this hypothesis in an epidemiological Health 2000 Cohort that
represents the entire Finnish population. The subjects were collected during 2000 and 2001
to assess the major public health problems, functioning and their determinants of the adult
Finns, aged 30 years or older. Childhood adversities were assessed with a questionnaire
containing a series of 11 questions regarding the childhood social environment before age of
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16. Relative LTL was determined from genomic DNA extracted from peripheral blood by a
quantitative real-time PCR-based method. After quality control, the sample consisted of
5799 individuals with information available on childhood adversities and LTL. Relatively
common childhood adversities were associated with shorter LTL at adult age, and this effect
can be detected in a nationally representative population-based cohort.
Dr Anke Hinney (Department of Child and Adolescent Psychiatry, University of Duisburg-
Essen) presented the results of the genome-wide analysis of rare copy number variations in
ADHD (Attention Deficit Hyperactivity Disorder). ADHD represents one of the most
common psychiatric disorders in children and adolescents with a worldwide prevalence rate
of 5.2 % (Polanczyk et al., 2007). A genome-wide CNV association study included 489
patients with ADHD and 1,285 population-based controls. Methods used were based on
Illumina SNP arrays (ADHD patients: Human660W-Quadv1, controls: HumanHap550v3).
Replication of the findings was conducted in an independent sample of 386 ADHD patients
and 781 healthy controls. In global burden analyses of rare CNVs stratified by their size, a
trend for an association between large (> 500 kb), rare (freq ≤ 1%) CNVs and ADHD. The
study revealed one genome-wide significant region within the PARK2 gene at chromosome
6 with a p-value of 1.18×10-4. Mutations and CNVs in PARK2 are known to be associated
with Parkinson disease.
Dr.Anita Thapar (Cardiff University) talked about a shared polygenic contribution between
ADHD in childhood and SCZ. This group has previously shown overlap of structural
genomic variation (CNVs) between SCZ and childhood attention deficit hyperactivity
disorder (ADHD). The present study investigated possible source of genetic overlap,
namely, common polymorphisms between ADHD, BD and SCZ. The study consisted the
recently published PGC GWAS analyses for SCZ and for BD as the discovery sets on which
to define polygenic scores that were assigned to each individual in the UK ADHD GWAS
data set (727 cases, 2067 controls). SCZ risk alleles were able to discriminate ADHD case
individuals from controls (p=1.04x10-4, R2=0.45%). They observed borderline evidence for
discrimination between ADHD and controls using bipolar disorder risk alleles (p=0.0519,
R2=0.11%). Strongest discrimination of ADHD cases from controls was provided by alleles
that were risk alleles for both SCZ and BD (p=9.98x10-6, R2=0.59%). The findings suggest
the genetic relationship of ADHD may be closer to SCZ than it is to bipolar disorder and
indicate the need for further studies of the genetic architecture of psychiatric disorders
across traditional diagnostic boundaries.
VI: Statistical Methods and Bioinformatics (reported by Eilis Hannon)
Dr.Nadia Solovieff (Massachusetts General Hospital) discussed the complication of neutral
variation in studies of rare variants. She proposed focusing the analysis on recent mutations
and introduced a methodology for classifying singleton mutations found in a case control
study as such. Data presented recovered 12% (of a maximum 20%) of validated de novo
mutations from a trios study. When applied to a population-based study, stronger
enrichments for synaptic and de novo gene mutations were found in the subset of loss of
function variants classified as recent for cases compared to controls.
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Dr.Robert Power (King's College, London) explored the SCZ paradox using SCZ polygenic
scores to predict reproductive fitness. A negative relationship was reported between the
polygenic score and number of grandchildren, indicating that SCZ variants are under strong
negative selection relative to other traits. In contrast, a quadratic rather than linear
relationship was found with the depression polygenic scores.
Dr.Daniel Howrigan (University of Colorado at Boulder) investigated whether runs of
homozygosity (ROH) contributed to SCZ etiology in the same way that common variants
do. Having performed region by region analysis for ROH, the top 7 regions all predicted
disease status. The combination of top ranked regions, akin to the polygenic score analyses,
were better predictors than a whole-genome measure. However these results were biased by
an individual's total ROH burden. After accounting for linkage disequilibrium, the results
were not significant.
Dr.Wesley Thompson (University of California) presented the ideas and mathematics behind
using a second GWAS to improve replication rates for genes with pleiotropic effect. He
showed increased inflation in a SCZ GWAS, through QQ plots, for SNPs already showing
some evidence of association with BP and vice versa. The relationship between these and
the false discovery rate allows more SNPs to be detected at genome-wide significance,
illustrated with the PGC datasets for SCZ and BP.
Dr.Danielle Posthuma (Vrije Universiteit) discussed how a gene's position in a molecular
interaction network and its structural properties can be predictive of how strongly it
influences disease, as seen in cancer genetics. Internet databases were mined for metrics
characterizing genes associated to monogenic diseases, complex diseases and those not
currently associated with disease. Monogenic genes were the most central in interaction
networks, with the highest connectivity, whereas non-disease genes were located on the
periphery. Although complex disease genes had more exons and isoforms this is probably
due to a bias in GWAS as larger genes are more likely to be significant.
Dr.Larmie Duncan (Harvard School of Public Health) compared 7 different annotation tools
for variants from the Swedish Exome study. All passed a proof of principle test that more
deleterious variants are less frequent in the population. In terms of variance explained,
Mutation Tester performed the best, but the difference between methods was small. Using
them in combination, for example by scaling all scores and adding, proved to be the best
method. Continuous metrics performed better than categorical, and where multiple
predictions were given, taking the worst was shown to be the best approach.
VII. Cross Disorder Screening (reported by Michael Way)
Results were presented of cross disorder and pathways analyses of the PGC genome wide
association datasets for SCZ, BP, MD, AUT and ADD of over 60,000 individuals with high
quality raw genotype data.
Dr Stephan Ripke (Massachusetts General Hospital; Broad Institute; Harvard University,
USA) explained the rationale for cross disorder analysis following a previous polygenetic
analysis1, showing significant genetic overlap between all five PGC psychiatric disorders.
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Interestingly, the results showed less genetic overlap between the childhood (ADD, AUT)
and adult (SCZ, BP, MDD) disorders. When the SCZ, BP and MDD datasets were combined
several loci met traditional significance levels (P ≤ 5 × 108). Predominantly, these loci have
been reported previously and include calcium channel and micro RNA (miRNA) genes. The
presenter finished by stating future plans such as replication of the combined SCZ, BP and
MDD meta-analysis findings within an independent data set with high quality raw genotypic
data.
Dr Phil Hyoun Lee (Massachusetts General Hospital, USA) gave findings from a network
and pathway analysis of miRNA target gene associations within the combined PGC disorder
datasets. The post-transcriptional regulatory functions of miRNA and their key roles in
cognitive decline and neuronal differentiation were presented. This was highlighted by PGC
findings in the SCZ cohort whereby nearly half of the strongly associated genes were post-
transcriptionally regulated by MIR-137. One of the aims of this study was to identify
miRNA targets enriched in the combined PGC dataset. Bioinformatic approaches were
undertaken including a set-based enrichment test (INRICH), functional expression analysis,
direct protein-protein interaction analysis and GRAIL text-mining. Significantly enriched
associations were observed for gene sets regulated by miR-9 and an overrepresentation of
expression of these genes was found in the brain.
Dr Gerome Breen presented findings from a combined pathway analysis of the PGC cross
disorder dataset. Gene sets were accessed from a variety of sources including KEGG, GO,
Reactome, PANTHER, OMIM and Targetscan. The presenter mentions how only 60% of
genes have a traditional pathway assigned. Different pathway analysis methods were used
including ALLIGATOR, INRICH, MAGENTA. Associations were found for different
pathways in each disease studied, however none met genome wide significance. Findings
included circadian rhythm pathways for ADD, digestive processes with AUT, cell junction
organisation with MDD, Histone H3-KL methylation with BP, and post-synaptic density
pathways with SCZ. A combined pathway analysis of different disease datasets was also
performed which proved to be more robust when the adult disorders (SCZ + BP + MDD)
were combined. 104 pathways met genome-wide significance, with significant overlap
between pathways implicating roughly a dozen independent processes, including the WNT
signalling pathway. When both adult and childhood disorders were combined nearly 800
overlapping pathways were significantly associated with disease, including the Ras pathway
and multiple processes involved in calcium signalling and the regulation of cell matrix
adhesion.
Dr S. Hong Lee (Queensland Brain Institute, AU) presented a novel approach for GWAS
pathway analysis using genomic partitioning by functional annotation of variance and
covariance. This approach includes all variants from a GWAS dataset, independent of their
effect size. Using an updated version of GCTA software and the combined PGC data, this
novel model was applied. Results found central nervous system (CNS) pathways and
processes were represented e.g. brain expressed-, synapse- and neuronal- gene sets. Normal
probability theory was used to test for significance with the finding that CNS pathway genes
were significantly associated with SCZ and BP in comparison with other genic and non-
genic SNPs.
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Dr. Naomi Wray (University of Queensland) discussed pleotrophy between single-
nucleotide polymorphisms (SNPs) for five psychiatric disorders. she sought to answer the
question of whether patients with psychiatric illnesses were more genetically related to each
other than to controls. She compared 12 million pairs of genes using “SNP-Chip”
technology to estimate heritability. To further add to the strength of the findings, a sanity
check was done by comparisons with Crohn's disease which yielded a bivariability of almost
zero. The highest bi-variability was seen in SCZ and bipolar disorder (BP). Fifteen percent
of patients first diagnosed with BP ended up with a stable SCZ diagnosis. Five percent of
schizophrenics ended up with a BIP diagnosis. Because of this diagnosis overlap, this
correlation was expected. The other top bivariability was seen with BP and major depressive
disorder. The study found a surprising negative relationship between autism spectrum
disorder and attention-deficit-hyperactivity disorder, which they were unable to explain. The
study was limited by a small sample size for the childhood diseases.
VIII: Epigenetics (reported by Katarzyna Mantha)
Dr. Vanessa Nieratschker (Central Institute of Mental Health, Mannheim, Germany)
reported on the influence of the epigenome on stress and its impact on developing
depression. She discussed the POSEIDON (Pre-, peri and pOstnatal Stress in human and
non-human offspring: a translational approach to study Epigenetic Impact on DepressiON)
study, which compares methylation patterns in humans, rodents and non-human primates
(Nieratscher et al., 2012). Dr. Nieratschker presented the results of methylated DNA
immunoprecipitation (MeDIP) analysis with a custom promoter tiling array and found 3,400
differentially methylation genes between highly stressed and non-stressed subjects. Twenty-
three genes overlapped between human samples and Rhesus monkeys. One gene, MORC1,
was found to be demethylated in all three species. Dr. Nieratschker emphasized new
candidates for stress-associated disorders can be found by using these technologies
(Rietschel et al., 2010).
Dr. Janice Fullerton (Neuroscience Research Australia, Sydney, New South Wales,
Australia) presented her study on the identification of genetic and epigenetic risk factors for
BP. She selected 39 genes (49 single nucleotide polymorphisms or SNPs) from the PGC-
GWAS; (Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium,
2011) for allele comparison between at-risk and control individuals using PLINK (Purcell et
al., 2007). Using a methylation array for at-risk and control individuals, Dr. Fullerton found
no significant differences in methylation status. Of interest, she observed two individuals in
her Risk Burden Analysis who she described as being in the “transition state” towards
bipolar disorder. When asked if she might further examine methylation differences in these
two individuals, she stated that this would give her low power, and it would be more
productive to wait until sample size increased.
Dr. Melanie Carless (Texas Biomedical Research Institute, San Antonio, USA) introduced
her study discerning the role of DNA methylation in memory and learning. She included
premorbid and first degree relatives in the assessment of methylation profiles (Carless et al.,
2011). Her collaboration with Dr. David Glahn (Yale University School of Medicine, New
Haven, USA) and Dr. John Blangero (Texas Biomedical Research Institute, San Antonio,
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USA) has led to a pilot project using 187 individuals and the assessment of 1,505 CpG sites
in 807 genes. Dr. Carless identified 22 associations with declarative memory, including
methylation within ALOX12 (memory-related) and BDNF (depression-related). An
overabundance of well-known Alzheimer disease genes was also identified, including APP
and APOA1 (spatial working memory).
Dr.Murray Cairns (The University of Newcastle Australia) noted that SCZ is a complex
neuropsychiatric disorder involving disturbances in neural circuitry and synaptic function.
While there are likely to be many genes and developmental pathways leading to the
neurobehavioural syndrome, the redundancy of these networks means that many
combinations of gene variants have the potential to play a role. Recent investigation has
revealed that post-transcriptional gene regulation and associated small non-coding
microRNA (miRNA) are likely to be important factors shaping the topography of these
networks. miRNA display complex temporospatial expression patterns in the mammalian
brain and have the potential to regulate thousands of target genes by functioning as the
specificity factor for intracellular gene-silencing machinery. Their dysregulation could also
lead to pervasive changes in the network structure during development and in the mature
brain that are significant in the pathophysiology of SCZ. This is now supported by
compelling evidence that the underlying miRNA biogenesis machinery and miRNA genes
themselves, are subject to disease-associated genetic mutation and epigenetic influence. He
examined the neurodevelopmental trajectory of miR-137 expression in the normal human
and rat prefrontal cortex, and the affect of this variant on cognition and cortical expression
of the mature miRNA. These analyses reveal a complex dynamic developmental expression
pattern and significant mutation associated changes in cortical expression and cognitive
phenotypes in SCZ. These findings are supportive of a role for miRNA in SCZ and suggest
that they may have significance as biomarkers or as targets for pharmacological
manipulation.
Dr.Roel Ophoff (UC, Los Angeles) performed a study using whole blood to gain a better
understanding of causal relationships between genetic variation and DNA methylation
profiles. To examine the association between DNA methylation and genetic variants,
genomewide genotype and DNA methylation (27K Illumina array) data was obtained from
whole blood of 260 SCZ patients and 240 healthy controls. For a subset of these subjects
array-based gene expression data was available as well. By combining epigenetic and gene
expression data they identified almost 700 CpG sites in the genome that are differentially
methylated between SCZ patients and unaffected controls, and of which methylation status
is associated with gene expression levels; moreover, these genes are also differentially
expressed between cases and controls. Genetic analysis revealed that some 8% of these
CpGs are under local (cis) genetic control. They hypothesized that identification of
biological relevant links between DNA methylation and gene expression in the context of
disease might serve as an efficient way to enrich for disease susceptibility loci if under
genetic control (methylation QTLs, mQTLs). They used the available results of the large
PGC SCZ genome-wide association (GWAS) study to examine whether the observed
mQTLs represent disease association signal. They observed significant enrichment of SCZ
association signals of mQTLs with the most significant effects for those loci that are also
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associated with differential gene expression in cases and controls. While the enrichment
effects were already visible when using nominal significant thresholds (p<0.05 in PGC) the
effects were amplified at more stringent values (e.g. p<1e-4). They identified five disease-
associated loci that control DNA methylation in cis, which in turn affect gene expression in
a case/control study. Interestingly.One of these loci was previously identified to be involved
in disease susceptibility in the recent PGC SCZ GWA study. Our results suggest that
enrichment of biological signal by combining genetic, epigenetic and gene expression
profiles from whole blood may be an efficient approach to identify disease susceptibility loci
including neuropsychiatric traits.
Dr.Torsten Klengel (Max-Planck Institute of Psychiatry) delineated an epigenetic
mechanism for a gene × environment (GxE) interaction of the FK506 binding protein 5
(FKBP5) gene with childhood abuse on the development of post-traumatic stress disorder
(PTSD) in adulthood. Data from this study were collected as part of the Grady Trauma
Project and replication was performed by the Conte Center Study for the Psychobiology of
Early-Life Trauma (Emory University, Atlanta, GA, USA). He showed that FKBP5
polymorphisms interact with child abuse exposure for the development of current PTSD
symptoms in adulthood. The risk to suffer from lifetime PTSD is significantly increased by
exposure to early trauma in FKBP5 risk allele carriers, but not in carriers of the protective
genotype. Pyrosequencing of bisulfite treated DNA of highly traumatized individuals and
controls revealed a significant demethylation of CpGs around glucocorticoid responsive
elements (GREs) of FKBP5 in abused individuals. Further, they found a significant
interaction of FKBP5 genotype and childhood abuse on DNA methylation levels in 3 CpGs
in intron 7 (F74,1=37.8, Pcorr<0.001). Replication in an independent cohort from the Conte
Center Study confirmed these findings. In a multipotent human hippocampal progenitor cell
line they demonstrated that FKBP5 demethylation is initiated by GR-activation with
dexamethasone which leads to a highly significant DNA demethylation in CpGs in intron 7
similar to the CpGs affected by early trauma in FKBP5 risk allele carriers (average of 17.1%
demethylation in the 3 CpGs, P<0.001). They extended these results comparing DNA
methylation changes in dexamethasone treated hippocampal progenitor cells with trauma
exposed individuals on Illumina's 450k methylation chip. In summary, FKBP5 increases the
risk of developing PTSD by allele-specific, childhood trauma-dependent demethylation of
CpGs in functional GREs of FKBP5. It is interesting that the effects on DNA methylation
seemed to be restricted to exposure to childhood trauma and were not influenced by
traumatic experiences in adulthood, suggesting a possible sensitive period in early
development for these epigenetic effects.
IX: Phenotypes/Endophenotypes (reported by Suzanne Gonzalez and
Eszter Kótyuk)
A. Cognitive/clinical endophenotypes
Professor Trevor Robbins (University of Cambridge) spoke on neurocognitive phenotypes.
These can be linked to unique neural circuitry that may become dysfunctional in a disorder.
Candiate gene studies try to identify association of there characteristics with one or more
genetic variants (risk genotypes). Well established endophenotypes refine diagnostic
Anderson-Schmidt et al. Page 24
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
classification and increase the power to identify specific causative genetic variants. As an
example, impulsivity contains impulsive choice, steeper reward discounting, delay aversion,
lack of consideration when making decisions, change in response criterion, and timing
impairment. Impulsivity is linked to the mesolimbic dopamine reward system (Buckholtz et
al., 2010) and the ventral striatum (Dalley et al., 2007). An animal model (Dalley et al.,
2007) suggests that a form of impulsivity in rats predicts high rates of cocaine self-
administration and is associated with changes in dopamine function before drug exposure.
Their data demonstrated that trait impulsivity predicts cocaine reinforcement and that D2
receptor dysfunction in abstinent cocaine addicts may be partly determined by premorbid
influences. According to these results on a clinical level high impulsivity could be a good
endophenotype for human stimulant abuse (Dalley et al., 2011; Ersche et al., 2010).
Impulsive control can be measured with Logan's stop-signal reaction time task (Aron et al.,
2003). When defining neural networks associated with ‘stopping’ impulsivity, the neural
circuitry that contributes to impulsivity could be an obvious objective in the search for
neurocognitive endophenotypes of drug addictions (Dalley et al., 2011). There is evidence
that ‘stopping’ impulsivity is a good endophenotype for stimulant drug addiction maybe
because impulsivity has the same underlying neurocognitive circuity as stimulant addiction:
Ersche et al (2012) found abnormalities in the fronto-striatal brain systems in both stimulant-
dependent individuals and their siblings without any history of chronic drug abuse
implicating that this neurocognitive region is of vital importance in self control. Other work
has identified seven networks underlying impulse control and found that different networks
were associated with different aspects of impulse control (Whelan et al., 2012). Their
findings suggest that impulsivity is a multi-dimensional construct, and it is plausible that
distinct brain networks contribute to different cognitive, clinical and behavioral aspects of
impulsivity.
He also discussed compulsivity an endophenotype linked to obsessive-compulsive disorder
(OCD), SCZ, and autism. Compulsivity contains stereotypy, rigid strategies or attentional
set, inappropriate persistence of habits (despite outcome devaluation or negative
consequences) and perseveration in reversal learning (Dalley et al., 2011). Compulsivity as
an endophenotype can be measured with cognitive flexibility tasks for example the
CANTAB ID-ED or the Wisconsin card-sorting test. It is clear from animal studies that the
prefrontal cortex has multiple functions in inhibitory control, a cognitive function closely
related to compulsivity. In monkeys lesions in different regions of the prefrontal cortex
caused loss of inhibitory control in different behaviors: attentional selection or affective
processing (Dias et al., 1996). Also, there is evidence from human fMRI studies that extra
dimensional set shifting and reversal learning involve different prefrontal cortex circuity
(Hampshire and Owen 2006). Studies have shown that OCD patients have reduced bold
response in the orbitofrontal cortex during reversal learning. It appears that compulsivity is a
good endophenotype for OCD (Chamberlain et al., 2006) but not for SCZ (Ceaser et al.,
2008). But there is cognitive impairment in SCZ as well which can be measured with
CANTAB self-ordered Working Memory task (Pantelis et al., 1997). The CANTAB paired
associates learning task is also a good endophenotype to measure and distinguish
hippocampal deficits in Alzheimer's disease, depression and dementia (Swainson et al.,
2001).Thus, Professor Robbins was emphasizing that using a cross-dimensional
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endophenotype approach instead of DSM defined categories make it possible to refine
diagnostic classification. Research should focus on dimensions and symptom clusters rather
than DSM categories. Researchers should employ several independent measures of the
examined theoretical construct. Research should be built on some prior familial basis for the
construct, it should combine objective behavioral, cognitive and neural measures to get a
good phenotype.
Dr. Ole Andreassen (University of Oslo and Oslo University Hospital-Ulleval, Oslo,
Norway) reported findings that TCF4 sequence variants and mRNA levels are associated
with neurodevelopmental characteristics in psychotic disorders (Wirgenes et al., 2012).
TCF4 mRNA expression level in peripheral blood was compared between a large sample of
patients with psychosis spectrum disorders and healthy controls. TCF4 risk variants were
tested for association using a linear regression model with characteristic psychosis
phenotypes (neurocognitive traits, psychotic symptoms and structural magnetic resonance
imaging brain morphometric measures). TCF4 mRNA expression level was significantly
upregulated in all psychotic diagnostic groups compared to controls. The rs12966547 and
rs4309482 risk variants were associated with poorer verbal fluency in the total sample.
There were significant associations of 14 other exploratory TCF4 SNPs with negative
symptoms, cognitive dysfunction and cerebellar volume in the SCZ sample, age at onset in
total patient sample and variants correlating with temporal cortical area and brain volume in
total sample. These results implicate TCF4 in psychosis, presumably related to abnormal
neurodevelopment.
Dr. Emma Knowles from the Yale University modelled cognition in a Mexican American
population (N = 1269, 63% female). She identified four quantitative trait loci (QTLs), of
which two QTLs (8q24.22 and 8q21.11) for working memory and general intellectual ability
on chromosome 8 reached genome-wide significance. Another two QTLs (17q23.2 and
17q24.1) identified on chromosome 17 were associated with spatial and general memory
performance. According to Dr. Knowles, a gene called HEY1 located at 8q21 is associated
with memory and β-amyloid metabolism. It might provide us some idea on the functions of
the identified QTLs.
B. Brain Imaging Endophenotypes
Dr. Sven Cichon (University of Bonn and Research Center Juelich, Germany) reported on
the systematic search for genetic factors influencing the thickness of the cerebral cortex, in
which the research group sought to identify gene variants contributing to inter-subject
variability in order to elucidate the molecular mechanisms underlying brain functions.
Genotypes were correlated with the phenotypic variability that was assessed through
magnetic resonance imaging (MRI) in a total of 158 healthy volunteers. They focused on
cortical thickness (CT) which is a heritable, quantitative trait, assumed to reflect the
architecture of neuronal and glial cells in the cortex (Winkler et al., 2010). They applied a
principal component analysis (PCA) on the pooled data from both hemispheres of 126
cortical regions. They performed a GWAS focused on 1st principal component, as it explains
60.7% of the observed CT variance. A total of 14 SNPs were identified in this discovery
phase and mapped to their respective region of interest (ROI). A total of 10 ROIs were
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identified. The top two SNPs located in 10q25 between SORSC1 and XPNPEP1 mapped to
the primary motor cortex of the posterior portion of the frontal lobe. The top SNP showed
association close to the formal threshold for genome-wide significance (P=6.98 E-8) and
was significant after correction for multiple testing using Monte Carlo simulations (P=0.04).
Other genes highlighted in this study are JARID2 (near DTNBP1) and ZNF804A, which
have previously been implicated in SCZ (O'Donovan et al., 2008; Pedrosa et al., 2007).
Dr. Sarah Medland (Queensland Institute of Medical Research, Brisbane, Australia)
presented results from the Enhancing Neuro Imaging Genetics through Meta-Analysis
(ENIGMA) Consortium, a network established in 2010 to bring together researchers in
imaging genomics to increase the understanding of brain structure and function. Imaging
and genetics protocols were developed to ensure data harmonization between working
groups (http://enigma.loni.ucla.edu/protocols/). The ENIGMA 1 Consortium performed
genome-wide association meta-analyses and replication for mean bilateral hippocampal,
total brain and intracranial volumes (Stein et al., 2012). Meta-analysis with ENIGMA
discovery and replication samples from the CHARGE Consortium resulted in an intergenic
variant rs7294919 (12q24.22) that was associated with hippocampal volume and rs10784502
within the HMGA2 gene was associated with intracranial volume. The working group
developed a freely available online interactive tool, EnigmaVis, in order to visualize the
association results alongside allele frequency, genes, and functional annotations (Novak et
al., 2012). They are currently under way with ENIGMA 2 which consists of 28 different
sites and over 13,000 individuals and focuses on seven subcortical regions and intracranial
volumes with a genetic focus on the 1000 genomes project (phase1 version 3) (1000
Genomes Project Consortium, 2010).
Dr. Stephanie Le Hellard (Centre for Advanced Study, Oslo, Norway) discussed
contributions from the Norwegian Cognitive Neuro Genetics sample (NCNG) (Espeseth et
al., 2012) in the polygenic deconstruction of psychiatric disorders with neurocognitive gene
sets. A GWAS was performed on a sample of 700 healthy individuals of Norwegian origin
which had been extensively phenotype for neurocognitive abilities and brain imaging,
followed by replication in an additional 4000 samples. Several studies were performed to
identify genes implicated in general cognition, in reaction time, speed of processing,
memory and in brain imaging. They selected gene sets associated to several cognitive
domains (general cognition, verbal abilities, speed of processing, reaction time, memory),
and identified and replicated significant enrichment across SCZ or bipolar disorder samples
for specific neurocognitive associated gene sets.
Dr. Vidar M. Steen (University of Bergen, Norway) led a discussion on the future of
genetics of imaging and neurocognitive phenotypes. The overall consensus is that
endophenotypes are very complex traits. The main driving force for power is sample size;
therefore, studies should have adequate samples and large collaborations are encouraged.
Stringent quality control measures and standardized protocols are needed.
Dr. Philip Mitchell (University of New South Wales) presented the latest findings of the BP
Kids Sibs longitudinal study in Australia. Subjects who were ‘at risk’ for bipolar disorders
(with at least one first-degree relative with bipolar disorder, N = 48) and healthy controls (N
Anderson-Schmidt et al. Page 27
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
= 49) performed a facial-emotion Go/No-Go fMRI task. The ‘at risk’ subjects showed
reduced activation at inferior frontal gyrus (IFG) when inhibiting responses to fearful faces
(p = 0.009, FWE-corrected). Association analyses revealed SNP rs10776799 in nerve
growth factor (NGF) was associated with the IFG activation (p = 0.071). SNP rs2283265 in
dopamine D2 receptor (DRD2) was associated with larger total cortex volume (p = 0.015)
and risk allele carriers of rs1006737 in CACNA1C showed increased grey mater density in
right amygdala and hypothalamus. These studies demonstrated the genetic basis of cognitive
deficits in siblings of patients with bipolar disorder.
Dr. Eva Janousova(University of Bergen, Norway) and colleagues applied sparse reduced-
rank regression (sRRR) model, a recently developed multivariate approach, to identify
genetic markers for SCZ in the Norwegian Cognitive NeuroGenetics sample (N = 440,
34.8% male). The sRRR model allowed simultaneous modelling of all genetic markers with
scores for the Digit Symbol Substitution (DSS) test, brain cortical thickness and surface
area. The sRRR model identified a set of 29 SNPs that were associated with the
neuroimaging traits, of which 14 of them assigned to genes as defined by Ensembl Version
54. One of the top-hit rs3911890 was mapped to SOX13 gene, suggesting its potential role
in neurodevelopment.
Dr. Falk Kiefer (Central Institute of Mental Health, Mannheim) illustrated the association
between SNP rs1327367 and responsiveness to alcohol cues in amygdala in alcohol-
dependent patients (N = 81, 57 males). SNP rs1327367 is located in a gene that encodes
transcriptional factor GATA4 in atrial natriuretic peptide (ANP). The risk allele carriers
(AG/ GG, N = 46) showed significantly lower alcohol cue-induced activations in amygdala.
As revealed by a survival analysis, the AA carriers are less likely to experience relapse in
alcohol drinking (p = 0.018). This study demonstrated the role of GATA4 in alcohol
addiction.
C. Neurochemical Factors
Dr. Jurjen Luykx from the University Medical Centre Utrecht and colleagues conducted the
first GWAS to identify genetic variants influencing the levels of NDMAR co-agonists –
glycine, LD-enantiomers of serine, proline and alanine in plasma and cerebrospinal fluid
(CSF) on 414 healthy subjects. Four genome-wide significant loci were detected around
genes encoding for transporters and enzymes including PRODH, SLC6A20 and DAO. In
addition, hypothesis-driven QTL analysis revealed the association between rs7598440 in
ERBB4 with the CSF GABA level in the subset of sample (N = 151, Luykx et al., 2012).
Despite the lack of replication sample as pointed out by Dr. Luykx, the results have
supported CSF as an informative target to study GABA activity in human.
X: Next Generation Sequencing (NGS) Studies (reported by Iordanis
Karagiannidis, Biju Viswanath and Michael Way)
Dr. David Porteous (University of Edinburgh) presented his NGS work on the DISC1 locus
in mood and psychotic disorders. Multiple previous studies (Bradshaw and Porteous 2011;
Chubb et al. 2008) have found this locus to be a genetic risk factor for many psychiatric
Anderson-Schmidt et al. Page 28
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2014 July 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
illnesses (e.g.: SCZ, bipolar disorder, major depression) and quantitative traits (e.g.: p300,
grey matter density, hippocampus volume). He presented his findings following a
comprehensive analysis of DISC1 structure-function and genotype-phenotype correlations
from resequencing 528 kb of the DISC locus in over 1,542 subjects (240 with SCZ, 221 with
bipolar disorder and 192 with recurrent major depression, plus 889 healthy controls who are
part of the Lothian Birth Cohort of 1936 (IQ measures at age 11 and repeat IQ, plus
extensive additional measures of behaviour and cognition at ∼70 years of age). All
individuals were sequenced to > 80% coverage and > 30-fold read depth. This analysis
identified 708 common and 2010 rare DISC 1 locus variants. Association analysis revealed
significant association of rs16856199 with recurrent major depression, but no evidence of
locus wide association with SCZ/bipolar disorder. This finding could not be replicated in a
community based sample..
Dr. Richard McCombie (Cold Spring Harbor Laboratory) highlighted the importance of
family genetics as a unique resource to minimize the time to find genes causing diseases.
Although case-control studies are very valuable, large sample sizes are required due to the
genetic heterogeneity contributing to psychiatric disorders. He explored several family-
based strategies, using both trios and extended families to identify candidate genes. He
described the exome sequencing of 57 SCZ trios, which identified significant enrichment of
denovo mutations in genes having important roles in epigenetic regulation and chromatin
modification (e.g.: MECP2, CHD8, MLL2, TDRD5). The significant overlap between
recent exome studies of SCZ (Hosak et al. 2012) and autism (Connolly et al. 2012) was also
noted. The combination of family studies followed by targeted sequencing in case-control
cohorts represents a powerful approach to understanding the genetics of psychiatric
disorders.
Dr. Fernando Goes (Johns Hopkins University School of Medicine) reported progress of a
large ongoing exome sequencing study of familial BP, using complementary family-based
and case-control methods. While GWAS studies identified possible common variants of
modest effect, ‘Bulls eye’ exome sequencing identifies low frequency/rare variants with
intermediate effect. Analysis of data from 322 cases and 435 controls was presented.
Bioinformatic annotation was performed using three programs: SIFT, VEST and Polyphen.
Top findings (e.g.: ARID4B, STX10, RFPL4B, ATP5A1, APP) were not genes implicated
in BP. Recent GWAS findings (Goes et al. 2012) were also not replicated. Pathway analysis
to test for enrichment of rare functional variants in gene ontology categories did not reveal
any significant findings. However, these findings are only an interim analysis. It is hoped
that increasing the sample size, ongoing family approaches, alternate analysis approaches
and focus on Loss of Function variants will identify more replicable findings.
Dr. Pamela Sklar (Mount Sinai School of Medicine) presented data from a large scale whole
exome sequencing study of BP in 1110 Swedish patients and 2438 matched controls from an
ongoing SCZ sequencing study. Genome-wide association studies (GWAS) focusing on
common single-nucleotide polymorphisms have pointed to a polygenic basis for BP(Sklar et
al. 2008). This study focused on the role of rare coding variation (single point mutations,
indels and structural variation), as assayed by high-depth next-generation sequencing.
Preliminary analysis has not revealed any single alleles of large effect, but has identified a
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small set of nominally significant genes. An attempt to replicate the top 25 signals in the
PGC (Sullivan, 2010) also did not reveal any significant findings.
Dr John Kelsoe (University of California, Department of Psychiatry, San Diego, USA)
presented findings from whole genome sequencing in an unusual BP family. The family had
an interesting inheritance pattern whereby the rare autosomal dominant disorder medullary
cystic kidney disease (MCKD) co-segregated with BP. Whole genome sequencing (30x
coverage) was performed in probands (affected individuals) with the focus on causative
mutations which mapped to linkage regions identified in this family. Several mutations of
interest were identified however a mutation within NTRK1, a receptor tyrosine kinase
involved with neurotrophic signalling stood out. Neurotrophic signalling processes have
been associated with BP and lithium response previously and the mutation likely prevents
SHC binding to a tyrosine on a phosphorylation domain crucial to protein function. This
finding led to a second stage deep re-sequencing effort (HiSeq2000, 1000X read depth) of
the NTRK1 gene and the functionally related NGF gene in a case control sample. This
yielded an increased burden of rare non-synonymous SNPs in NTRK1 and NGF, however
for more common SNPs there was no mutational burden.
Dr James Potash (Carver College of Medicine, University of Iowa, USA) presented findings
from whole exome sequencing of families and case control samples from what is now the
Bipolar genome Study (BiGS). Exome and synaptome promoter sequencing was performed
in eight large families with 80% coverage at a 20x read depth. The primary goal of this
study was to identify “low hanging fruit” i.e. rare variants which are predicted to be
damaging and segregate within families. Numerous loci (C3AR1, TADA1, AAPL1) with high
risk mutations were identified, however nominal association signals were obtained giving
little statistical power to the findings. An analysis of familial segregation of these as well as
loci identified from genome wide association studies (CACNA1C, ANK3) was also
performed. Some markers marginally segregated, and these results did not survive multiple
correction. The best candidate genes from this study are ABHD12B, CDK1S, DCHS1
however he concluded that there were no “low hanging fruit” in these data.
Dr Margit Burmeister presented a summary of the research aims and on-going findings from
the Bipolar Research in Deep Genome and Epigenome Sequencing (BRIDGES) study. One
of the primary goals of this study was to develop novel approaches for analysing whole
genome sequencing datasets. Sequencing was performed with 8-10X coverage in 1600
European Bipolar type 1 cases and 1600 screened controls. High levels of quality control
were undertaken in this study to avoid sources of experimental error including DNA
extraction from blood, using principle component analysis and the use of bar coded plates.
The primary result was that there was no excess of rare variants where common associations
have previously been reported through GWAS. Secondary to this a SKAT 5 gene based test
was also performed with no significant findings.
Dr Seth Ament (Institute for Systems Biology, USA) presented findings from the family
genome sequencing project. The primary hypothesis underlying this study was that
sequencing within multiplex families provides an efficient route to family-specific genetic
causes of BP. Whole genome sequencing was performed (60x coverage) on 142 individuals
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from 23 multiplex pedigrees. KAVIAR 6 and Ingenuity variant analysis were used to
analyse novel variants that co-segregate with diseases in each family. Missense mutations
were identified within CHRNA3, ARVCF, NEGR1. An extremely rare SNP (MAF < 0.001)
was identified in CACNA1C resulting in a non-synonymous mutation (R1973Q). An
analysis of most frequently mutated genes in eight families with BP also provided strong
support for CACNA1C. A gene ontology analysis identified cell adhesion and nerve impulse
processes overrepresented in the dataset. Another analysis was performed to test the
monogenic nature of BP. This led to combined genome sequencing and linkage analysis in
search for segregating variants in familial samples. However, no promising hits were
identified. In summary, a variety of methodologies were presented for identifying causative
mutations in familial samples.
Dr. M. O' Donovan (Cardiff University) presented an approach to de novo mutations in SCZ
using whole exome sequencing of 586 trios from Bulgaria. In order to partition the genomic
variance attributable to SNPs in pathways he used the updated Genome wide Complex Trait
Analysis tool. No substantial differences for rates of all classes of de novos across studies
were observed. Weak enrichment for de novos compatible with a highly heritable disorder
was observed.These data supported the specific synaptic pathways that were previously
reported from de novo CNV analyses.
Dr. Guy Rouleau (University of Montreal) presented an approach for revealing the
contribution of de novo mutations in developing specific neurodevelopmental disorders such
as SCZ, Autism spectrum disorders (ASD) and Intellectual deficiency (ID). He focused on
the role of synaptic genes in the pathogenesis of the disorders (“Synapse – to –Disease”
project). He found 28 singletons haing spontaneous mutations, some of which may be
disease causing. On phase 2 of the project, four nonsense mutations were identified with
exome sequencing at 14 trios from France. Both studies showed that de novo mutations can
explain part of the missing heritability. More work is required for defining the pathways and
the specific genes that predispose to these diseases and also that there must be significant
genetic overlap between SCZ, AUT, and ID.
Dr. Aarno Palotie (Wellcome Trust Sanger Institute) presented a sequence analysis of SCZ
and ASD in the UK10K Project. For SCZ a total of 1700 cases have been gathered and also
430 familial cases form Finland including 150 samples from the Kuusamo isolate. For ASD
over 800 cases have been selected. Then some results from a smaller sub-study of 77 autism
trios (using the De Novo Gear Program) were shown. The de novo rates seemed to be
consistent with other projects. A loss of function variant was recognized in the CACNA2D3
gene. In the SCZ Finnish families, they found 8 of 22 families had a novel loss of function
variant co-segregating with the disorder and also 4 individuals had a homozygous deletion
on 22q11.22.
Dr. Shaun Purcell (Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts
General Hospital, Boston, Massachusetts, United States of America) spoke about a whole
exome sequencing approach in 5023 cases and matched controls from a Swedish cohort.
More deleterious alleles tend to have lower sample frequency. Analyses of genesets revealed
the occurrence of true associations that may hide in the genome-wide distribution.
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Intersection of the data with protein-domain annotations and also the use of the identity by
descent approach, combined with sequencing data can be used to detect de novo mutations.
There is clear evidence for convergent genetic signatures in SCZ across CNV, GWA, de
novo and population level exome sequencing studies and it will be necessary to combine
these signals.
XI.Substance Abuse and Environmental Stress
Dr.James Dee Higley (Department of Psychology, Brigham Young University) focused on
an insertion/deletion polymorphism in the promoter of the serotonin transporter gene 5-HTT
which moderates the effect of early life stress on depression. In humans, individuals who
carry the short allele (the deletion) exhibit more depressive symptoms in response to early
life stress than those who are homozygous for the short allele (Caspi et al., 2003).
Furthermore, this polymorphism is conserved in the rhesus macaque (Macaca mulatta)
where it also interacts with early life stress (Bennett et al., 2002). Dr. Higley began by
explaining the importance of mothers in primate development. Maternal care is the primary
interaction in the social world. Mothers provide the input at the necessary time for normal
cognitive development; each material input coincides with brain development at that time.
Without mothers (i.e. if macaques are peer-raised), infants are clingy, anxious and
impulsive. Further, the levels of CSF 5-H1AA (a serotonin metabolite) are increased in long/
long individuals vs. long/short who were peer-reared, and also over both genotypes who
were mother-reared. Also, depressive and anxiety phenotypes increase over 4 weeks in long/
short, but not long/long infants.
The interaction of the polymorphism (termed 5-HTTLPR) with early life stress is well
replicated in primates, but humans have proved difficult to show an association. A meta-
analysis found no interaction between 5-HTTLPR and early life stress (Risch et al., 2009).
However two subsequent meta-analyses did find an interaction, but the effect size was quite
small. This may be because of the heterogeneity of human environments. In non-human
primates, the environment is much more controlled
A primate model is ideal to study gene by environment interactions with alcohol. Long-term
alcohol abuse has a heritability of between 50-60% (Ystrom et al., 2011). Dr. Higley's model
of non-human primate alcohol abuse uses a sweetened alcohol solution and vehicle available
to the macaques for five days a week for one hour per day in the home cage. Ten to 20% of
the subjects drink to intoxication, whereas five to ten percent are averse to drinking. At first
glance, it seemed that there was no effect of 5-HTTLPR genotype on in the ethanol intake of
peer-rear vs. mother-reared macaques. However, when the rate of alcohol intake over six
weeks was measured, the peer-reared long/short individuals showed a significant increase in
intake over the other three groups at week six. Dr. Higley also showed a single-cage effect:
the individuals caged alone drink more alcohol when peer-reared.
Aggression was measured using the monkey intruder paradigm. A macaque unknown to a
group is placed in a cage next to the group cage of interest and aggressive behaviors are
measured. All test subjects are the same sex. In males, aggression is directed toward the
intruder, whereas in females it is directed to cage mates. In general, males are more
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aggressive than females, however; long/short males are more aggressive than any other
group. Furthermore, aggression is escalated in the test animal if the intruder has the short
allele. Females that have the short allele are aggressive to others in their cage.
Corticotrophin-releasing factor (CRF/CRH) is the primary initiator of the HPA axis, and
causes anxiety when injected. Peer-reared monkeys show more CRF which increases across
weeks of separation. A SNP in the Crf gene was shown to correlate with increased ethanol
intake. Also, the high-activity MAOA genotype showed more ethanol consumption.
In conclusion, Dr. Higley's emphasized several major themes: Genes may be expressed
differentially depending on the environment. Primate studies are very useful in that they
account for double the variance (7-15%) when considering gene by environment
interactions. Particularly, the homogeneous rearing and situational settings may in part
account for some of the additional variance and explain some of the human studies failure to
replicate. Interestingly, genotype of the initiator and the recipient must be considered in
social interaction. Similarly, sex must be considered, especially when genotype is involved.
Finally, the type of stressor is of importance when considering genotypic effects on
behavior.
XII: Animal Models (reported by Laramie Duncan and Benjamin I Laufer)
Dr. Kerstin Lindblad-Toh (Science for Life Laboratory Uppsala and the Broad Institute of
MIT and Harvard) described findings from research about genetic influences on behavioral
phenotypes in dogs. She explained that dogs are a useful model organism for behavioral
phenotypes because of the way in which their phenotypes were shaped. Specifically, modern
dog breeds exist as a result of selective breeding for desired traits such as herding, wrinkled
skin, and retrieving, among many others. Selective breeding imposes severe selection and
results in genes of relatively larger effects on phenotypes than those seen in humans.
An important consequence of the larger effect sizes (for loci affecting behavioral phenotypes
selected in dogs) is that substantially smaller sample sizes are needed to identify genome-
wide significant loci. For example, hundreds of samples can be used instead of tens of
thousands of samples. Specific results were reported for dog domestication genes in a
sample of 12 wolves and 60 dogs (from 5 different breeds). In this sample they identified 39
regions with 129 genes that met criteria for genome-wide significance. When these genes
were further analyzed to determine which functional categories were overrepresented, two
pathways emerged: 1) nervous system development, and 2) digestion. These pathways are
interesting because they make sense in light of dog domestication.
In particular, Dr. Lindblad-Toh's group hypothesized that advantageous mutations in genes
involved in the digestion of starch would have been selected for given their effect on dogs'
ability to benefit from consuming humans' food. Consistent with this idea, they found
evidence implicating mutations in genes in three key components of the starch digestion
pathway: MGAM (maltase digestion), AMY (amylase), and SGLT1 (sodium glucose co-
transporter 1). Her approach involved identification of increased FST and decreased
heterozygosity, which are both signatures of selective sweeps.
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Dr.Clarissa Parker (University of Chicago) presented her groups research on advanced
intercross lines in rodent models (AIL) that give the advantage of splitting up genetic
linkage and allowing for a higher mapping resolution (Parker et al., 2011). In this research
they use their model to examine the acquisition of learned fear, which is heritable and more
difficult to extinguish in humans with post-traumatic stress disorder (Zovkic and Sweatt,
2012). They used two genetically distinct AIL populations to fine-map QTLs associated
with fear conditioning. Using this model they examined whether any QTLs were associated
with tone shock conditioning using the package r/QTLRel (Cheng et al., 2011). By
exploiting the increased recombination frequency of their AIL, they replicated and mapped
QTLs with greater precision than previous approaches and identified multiple candidate
genes. Ultimately, their approach can be generalized to many high throughput phenotypes.
They hypothesize that the use of outbred strains in combination with GWAS could vastly
accelerate the process of gene identification, as it causes a breakdown of linkage
disequilibrium.
Currently, there is an incomplete catalogue of mouse CNVs and the objective of Jin
Szatkiewicz's (University of North Carolina at Chapel Hill, USA) groups' research is to
generate a comprehensive (162 strain, high resolution) and accurate (large scale validation)
mouse CNV catalog. In their catalogue they sought to have 100 classical strains and 62 wild
derived strains. This allows them to see both rare and common variants and use a
population-based approach to discover CNVs. They conducted a genome-wide survey of
CNVs using the Affymetrix Mouse Diversity Genotyping Array (Yang et al., 2009). They
developed an analysis protocol that combined microarray data with computational
algorithms and genomic resources to predict CNVs. In total, 1,499 copy number variant
regions (CNVRs), spanning 1.5% of the mouse genome, were observed. This use of this
catalogue for psychiatric genetics was exemplified by the groups establishment of the copy
numbers across the 162 strains for Glyoxalase 1 (Glo1), as a duplication of Glo1 has been
implicated in anxiety-like behavior in mice (Williams et al., 2009). The Sanger data (http://
www.sanger.ac.uk/resources/mouse/genomes/) contains the sequence for 17 inbred strains
and data on the CNVs present and has the potential to be used for validation of the groups
results.
Recent research has found a genome-wide association between the Neurocan (NCAN) gene
and bipolar disorder (Muhleisen et al., 2012). NCAN is one of few genes observed to be
associated with both bipolar disorder and SCZ. Given that there is the same risk variant for
two different disorders, these preliminary findings hint that NCAN has integral brain
functions. The aim of Dr. Sandra Meier's (University of Bonn, Germany) groups' study was
to characterize NCAN by exploring the behavioral phenotype of Ncan knock-out (Ncan-/-)
mice. They found that the NCAN risk allele is associated with the mania factor dimension,
in particular with the sub-dimension of over-activity. Ncan-/- mice showed behavioral
abnormalities strikingly similar to human mania endophenotypes, which were found to be
reversible by lithium treatment.
ZNF804A has been identified as a candidate gene for SCZ and BP in replicated GWAS
studies (Steinberg et al., 2011) and through patient specific searches for CNVs. It has a
DNA binding domain, which suggests that it can act as a transcription factor. Using a gene
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knockdown approach in neuronal precursor cells and RNA-Sequencing, Dr. Herb Lachman
(Albert Einstein College of Medicine, USA) reported that ZNF804A appears to affect
GABA subtype neurons, genes involved in metabolic syndromes, and genes implicated in
nicitine and alcohol dependence. Furthermore, some of the genes affected by ZNF804A may
be influenced in an opposite manner depending on the differentiation state of the cell (neural
progenitor vs neuron). This bimodal regulation is typical of the Kruppel-like family of Zinc
finger transcription factors (such as ZNF804A), which can activate or represses the same
gene depending on the presence of other transcription factors.
XIII. Functional Consequences of Gene Variants (reported by Olga
Beltcheva and Helen Spiers)
NEWMEDS was presented by the chair as the biggest ever collaboration between Big
Pharma and Academia, aiming to develop a translational platform and tools for psychiatric
drug development. Dr. Hrein Stefánsson, deCODE Genetics, talked about “Recurrent CNVs
affecting fecundity” and presented the findings of the SGENE project. While studying copy
number variations recurrently associated with SCZ, the SGENE team noticed that the
carriers of some variants had fewer offspring - mutations under negative selection. By
focusing only on recurrent, negatively selected CNVs they identify 55 potentially interesting
CNV with frequency of less than 1% and tested them for association with SCZ, bipolar
disorder and autism developmental delay. So far they have found an association with one
variant – a duplication 10q11.22-23, which is very rare and associated with high risk.
Another part of Dr. Stefánsson's work within NEWMEDS is phenotyping population
controls that carry CNVs under negative selection with the aim to define a phenotypic stamp
of these genetic variants and search which neuronal systems are affected by them. One
region of interest is 15q11.2 - deletions in this region are associated with selective learning
disability. One candidate gene located in this area is the CYFIP1, which has been shown
recently to cause fragile X like phenotype in mice Bozdagi et al. 2012. At present expression
studies are underway as well as fMRFI in the affected subjects for complete elucidation of
the effect of 15q11.2 deletion.
Dr. Andreas Meyer-Lindenberg, University of Heidelberg, Mannheim, presented his work
on “Gene dosage effects of a CNV associated with SCZ risk on brain structure”. Being part
of the NEWMEDS Collaboration, he and his group are working on detailed imaging
phenotyping of 70 individuals with rare CNV identified by the deCODE Genetics' study
described above. Dr. Meyer-Lindenberg argued that due to the mechanism of CNV
generation the same chromosomal region could be affected by both deletions and
duplications, which in some domains may result in exactly opposite phenotypes. They set
out to study these dosage effects of CNV mutations in different brain previously associated
with SCZ using Voxel-based morphometry Radua et al. 2012. Several brain structures were
found to have increased volume in cases with duplications and decreased volume in cases
with deletions. Some of these areas are similarly affected in SCZ patients.
Dr. Jacob Nielsen, H. Lundbeck A/S, presented his work entitled “A mouse model of
15q13.3 microdeletion syndrome recapitulates several phenotypes of human syndrome”. It is
based on a study of the SGENE project discussed above, that identified an association of a
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microdeletion in 15q13.3 with SCZ). As expected, a downregulation of the six genes located
within the CNV was observed in the deletion carriers. No gross abnormalities in the brain
were found, which is in agreement with findings in SCZ patients. A marked change in
seizure pattern was seen in the transgenic mice, very similar to that described in human with
15q13.3 syndrome Muhle et al. 2011. In addition, the CNV carriers were found to have no
learning disabilities, but displayed long term memory deficit and higher levels of aggression.
Further tests (imaging, in vivo electrophysiology, cognition and heart rhythm) are under
way.
Dr. Michelle Rosgaard Birknow, H. Lundbeck A/S, presented “A mouse model of 15q13.3
microdeletion syndrome display pre-attentive processing deficits and EEG phenotypes seen
in SCZ”. She described in details the EEG findings of the mouse model introduced by the
previous speaker. The goal of the study was to evaluate the specific deficits in the mice and
check if they mirror the electro physiological endophentoypes in human SCZ patients. They
recorded and analyzed in detail auditory evoked potentials in multiple assays. It was found
that the 15q13.3 deficient mice display preattentive processing deficits. The observed EEG
phenotypes were found to be similar to those in individuals with psychiatric disorders like
SCZ.
Dr Collins (University of North Carolina) addressed whether miR-137 could contribute to
SCZ pathogenesis through regulating cellular pathways. Human neural stem cells (ReNcell-
VM) were transduced with vectors to induce over expression or inhibition of miR-137, or
control vector. Cells were collected at 24 or 48 hours post-transduction and RNA
sequencing performed using Illumina HiSeq 2000 technology. Genes differentially
expressed between cells exposed to control or over expression vector were identified at both
time points; at 24 hours, 310 genes were identified, 12% of which were predicted miR-137
targets. At 48 hours, 538 genes were identified, 19% of which were predicted miR-137
targets. Pathway analysis of down-regulated genes revealed an enrichment of cell-cycle
genes, consistent with previous findings which have suggested a role of miR-137 in cell
cycle regulation. Finally, Dr Collins found an enrichment of her findings in the results of
previous SCZ GWAS, providing further support for an involvement of miR-137 in SCZ
pathogenesis.
Dr. Janine Arloth (Max-Planck-Institute of Psychiatry) described data on identifying single
nucleotide polymorphisms (SNPs) associated with changes in gene expression regulated by
glucocorticoid (GC) (cis-eQTL analysis). Peripheral blood was used to genotype and
measure the gene expression profile of 160 male Caucasians (69 cases, 91 controls) at
baseline and three hours following stimulation of GC using 1.5 mg dexamethasone. Of a
total of 4,395 significant cis-eQTLs, 2,364 significant response eQTLs were identified,
>67% of which were located >200 kb from the probe at a mean distance of 406 kb. This was
in contrast to baseline eQTLs, which had mean distance of 136 kb, suggesting long-range
regulation of gene expression by the glucocorticoid receptor (GR). Additional analysis
revealed an enrichment of the GC response element and transcription factor binding sites
that modulate GR signaling near eQTL SNPs. Moreover, it was found that response eSNPs
were significantly more likely to be associated with major depressive disorder than random
or baseline eSNPs (P<0.001).
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Dr. Lutz Priebel (University of Bonn) investigated the effect of genetic variation on gene
expression (expression quantitative trait loci, eQTLs) using a unique sample of 148 pre-
mortem human hippocampus samples derived from treatment-resistant epilepsy patients.
Whole-genome SNP (Illumina Human660W) and gene expression data (Illumina
HumanHT-12v3) was generated, as well as genome-wide methylation data (Illumina
HumanMethylation450 array). Dr Priebel identified 78 trans-regulating eQTLs (defined as
>1 Mb between SNP and probe) that withstood multiple testing correction, and 1,925 cis-
regulating eQTLs (defined as ≤1 Mb between SNP and probe) that remained significant after
permutation-based Westfall-Young correction. Additionally, the analysis investigated the
influence of DNA methylation on gene expression, finding that nearly a quarter of eQTLs
were also mQTLs. Dr Priebel hopes to fully integrate the methylation, probe and transcript
data, producing a resource allowing greater annotation of GWAS findings.
To detect cis-acting effects on gene regulation, Dr Nicholas Bray (King's College London)
measured the relative allelic expression of 5 candidate genes in up to 12 brain regions taken
from 20 unrelated adult subjects. For every gene, significant differences in allelic expression
between brain regions within subjects were found. Elaborating on this finding, Dr Bray
investigated whether allelic expression differences occurred between cell populations, and
found ZNF804A displayed significant differences between cells of the CA1 and the dentate
gyrus. Adult human brain samples were then used to interrogate the cis-effects of a genome-
wide significant risk variant for SCZ (rs1344706) on ZNF804A expression. However, no
significant effects were found in any of the brain regions investigated. Conversely, when
exploring the effect of this risk variant in fetal brain tissue, it was found to be associated
with altered allelic expression from the second trimester. Dr Bray's work highlights the
differing regional, temporal and cell-specific effects of cis-regulatory variation.
Dr Douglas Levinson (Stanford University) presented on behalf of Professor Alexander
Eckehart Urban and highlighted the concern that there may be an increased rate of de novo
CNV formation in induced Pluripotent Stem Cells (iPSCs), potentially altering the utility of
this system when studying the genetic basis of psychiatric disease. To address this concern,
Professor Urban and colleagues performed a whole-genome and RNA sequencing based
CNV analysis in fibroblast samples and iPSC lines from two families, finding that on
average an iPSC line would have two lineage-manifested CNVs (CNVs not found in the
fibroblast culture from which the iPSCs were derived). The presence of the same CNVs in
the fibroblast tissue of origin was investigated, finding that >50% of the detected LM-CNVs
were already present in the fibroblasts, suggesting that de novo CNVs in iPSCs are not
necessarily the result of reprogramming. Using whole-genome sequencing is therefore
important when using iPSC-models to identify potential genetic confounds.
Dr. Melvin McInnis (University of Michigan) reported on the development and
characterization of iPSC lines from controls and phenotypically-assessed individuals with
bipolar disorder. Subjects from the Prechter Bipolar longitudinal study with high versus low
levels of neuroticism were selected for dermal biopsy. The results presented were produced
with 44 iPSC lines (24 of which are from patients with bipolar disorder) derived from 12
fibroblast stocks taken from five individuals. Testing for microRNA expression differences
between iPSC lines derived from controls versus individuals with bipolar revealed
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approximately 1000 genes with nominally significant expression differences. Additionally,
functional annotation of the iPSC colonies identified an overrepresentation of transcription
factors in cell lines from individuals with bipolar disorder versus controls. These cell lines
provide an opportunity to model complex neuropsychiatric illness, and can be used to
further characterize the genes which are differentially expressed between bipolar and control
cells, particularly at sequential stages of differentiation.
XIV. Immunogenetics (reported by Katri Kantojärvi)
Dr Bernhard Baune (University of Adelaide) discussed several studies in the field of
immune system in emotion and cognitive processing. Immune factors contribute to
molecular mechanism of learning, memory and emotion processing. A contribution of
immune genes is highly relevant since observation have been made that cytokines directly
interact with molecular mechanisms of memory, learning and neuroplasticity in the
hippocampus and the amygdala in particular, both of which are highly relevant to emotion
and cognitive processing. In the study of inflammation and emotions IL-1β gene was
associated with reduced affective reactivity (Baune et al. 2010) Several studies have noticed
the association between genes of inflammation and cognitive performance. Genetic
polymorphisms of cytokines play an important role in cognitive functioning in healthy
elderly humans. In a study among healthy elderly from the general population, the
chemokine IL-8 was significantly associated with poor cognitive performance in the
memory, attention and motor domains. In a similar study among healthy elderly individuals,
genetic variants of IL-1beta were related to poor memory, whereas a genetic variant of TNF
was associated with better cognitive speed performance. In contrast, IL-6 showed no genetic
association with cognitive performance in humans so far. Moreover, genetic variants of
cytokines may play an important part in predicting anti-depressant treatment response. In
different studies, it was shown that the genetic polymorphisms of IL-1beta and IL-11 may
play a key role in antidepressant treatment response and emotion processing (IL-1beta)
mediated by the amygdala in depression. Immunogenetic research appears to be a promising
area for characterizing the predisposition to psychiatric disorder, identifying disease and
treatment biomarkers and developing interventions. Immune factors might be suitable
treatment targets in depression and cognitive impairment.
Dr Bernhard Baune (University of Adelaide) replaced Dr. Udo Dannlowski (University of
Marburg) and presented a study of the immune system in neuroimaging. The aim of the
study was to clarify whether genetic variation in genes coding for cytokines such as Tumor
Necrosis Factor α (TNFα) or Interleukin 6 (IL6) can be linked to neuroimaging markers
relevant for depression or other neuropsychiatric disorders. They employed voxel-based
morphometry (VBM) in a large sample of well characterized healthy individuals (N=303) to
analyze the associations between genetic variants of TNF (rs1800629; rs361525), genetic
variants of IL-6 (rs1800795; rs1800796, rs2069833, rs2069840) and brain morphology (gray
matter concentration). No subject had a life-time history of a psychiatric disorder, auto-
immune or chronic inflammatory disorders, chronic infections or any other relevant medical
conditions. The findings suggest a neurodegenerative role of the A-alleles of the TNF SNPs
rs1800629 (-308G/A) and rs361525 (-238G/A) on hippocampal volumes in healthy
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individuals. However, a neuroprotective role of the G-allele of the SNP rs1800795 on
hippocampal volumes could be discerned. Studies of clinical populations are underway.
Dr. Patricia Zunszain (Centre for the Cellular Basis of Behaviour; King's College London)
discussed molecular aspects of the immune system in depression. Depressed patients have
higher levels of proinflammatory cytokines, particularly TNF-α, IL-1β and IL-6.
Administration of pro-inflammatory cytokines causes changes in behavior which closely
resemble symptoms observed in depression. By using a clinically relevant model of human
hippocampal progenitor cells, in this study the effect of cytokines both on the regulation of
neurogenesis and on possible neurobiological pathways that are involved in depression were
investigated. The cytokine effects on all enzymes involved in the kynurenine pathway was
also analyzed. The enzyme indoleamine 2,3-dioxygenase (IDO) appears to be a key player,
as it initiates the pathway by degrading tryptophan to produce kynurenine, which can then
lead to neurotoxic or neuroprotective products. The differential regulation of these
compounds is postulated to explain the behavioral changes experienced by some patients
during exposure to inflammatory stimuli. Increasing IDO, IL-1b reduced the availability of
tryptophan, the precursor of serotonin. Additionally, it promoted the production of enzymes
conducive to toxic metabolites. The detrimental effect of IL-1b on neurogenesis was
partially recovered by blocking the neurotoxic pathway. The results suggested that inhibition
of the kynurenine pathway may provide a new therapy to revert inflammatory-induced
reduction in neurogenesis. Finally, the anti-inflammatory effect of antidepressants from
different chemical classes was investigated. Inflammation was induced into the cell model
by incubation with IL-1b, and the inflammatory response was quantified by measurement of
IL-6 secreted into the supernatant, and also by looking at auto-induction of IL-1b and IL-6
as mRNA. These results add further evidence for the differential anti-inflammatory
properties of antidepressants.
Dr Sarah Cohen-Woods (Institute of Psychiatry, King's College London) discussed
childhood stress-reactivity and inflammatory mechanisms in clinical major depressive
disorder (MDD). The stress pathway interacts directly with the inflammatory system, and
childhood maltreatment has been consistently associated with depression and with an
enhanced inflammatory response. The aim of the study was to investigate if genetic
variations in inflammatory genes (CRP, IL-1B, IL-6, IL-11, TNF, TNFR1 and TNFR2)
interact with environmental exposure to childhood maltreatment to predict risk of
developing recurrent MDD. The sample consists of 262 individuals with recurrent moderate
to severe MDD (ICD10/DSM-UV), and 288 unaffected individuals screened by
questionnaire and telephone interview for absence of psychiatric disorder. The Child
Trauma Questionnaire was completed to assess exposure to sexual, physical and emotional
abuse, and physical and emotional neglect. DNA was extracted from blood or cheek swabs
and genotyped externally using the Illumina Human 610-Quad bead chip, and imputed
against the publically available 1000 genomes data. None of the studied genes showed main
effects, althou childhood maltreatment was significantly associated with depression. Two
genes presented no evidence for interaction (IL1-B, and IL11) while the remaining ones did
present some evidence for interaction. The SNP effect occurred in one of two ways - either
risk or protection. For genes IL6 and CRP minor allele increased risk of depression in
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individuals exposed to childhood maltreatment, while the other three were protective. All
interaction models tested were additive. This could lead to novel interventions and
pharmacological targets; this is particularly salient as a history of childhood maltreatment is
also associated with reduced pharmacotherapeutic response.
XV. Comorbidities (reported by Mariko Brandon)
Preben Bo Mortensen (Aarhus University) focused on observations of four different somatic
comorbidities as clues for the etiology of SCZ. The four main comorbidities were cancer,
autoimmune disorders, infections, and epilepsy. Patients with psychiatric disorders had a
decreased incidence of cancer, but increased morbidity from cancer, which could be the
result of decreased access to diagnostic or treatment options. However, the findings should
be taken with caution because similar studies have yielded conflicting data. An increase in
autoimmune diseases in the schizophrenic population was reported. It was speculated that
antibodies that are responsible for the pathophysiology of many autoimmune diseases might
also be responsible for the neural degeneration seen in schizophrenics. A direct relationship
for increased epilepsy and infections was also seen, with the theory offered that the blood-
brain barrier is decreased with infection, increasing susceptibility to antibodies. Limitations
to the work include survivor bias, detection bias in the rates at which cancer and SCZ are
diagnosed, and confounding variables such as lifestyle. Although siblings were studied,
familial comorbidities were not quite well-established.
Christoph Lang (Harvard School of Public Health) focused on causation and causal
interference in genetic epidemiology. Using SNPs, they explored an association between
lung cancer and smoking that goes beyond environmental and pathological links Could there
be genes that code for an increased propensity to smoke, in addition to an increased risk of
lung cancer The findings were ultimately found to be inconclusive. A possible explanation
was that increased body mass index has been suggested to predispose to nicotine addiction.
Manuel Mattheisen (Harvard Medical School) looked at 4 asthma phenotypes and causal
pathways for depression. However, no obvious gene with a statistically-significant
correlation was found. The explanations behind the lack of findings were a small sample
size (n =387) and anxiety as a compounding variable. The group next plans to also study the
relationship between depression and chronic obstructive pulmonary disease.
XVI: Large Existing National and International Datasets and Cohorts
(reported by Vanessa Nieratschker)
Dr.Heike Anderson-Schmidt (University of Göttingen, Germany), described the German
Association for Psychiatry and Psychotherapy (DGPPN) Cohort Study. This nationwide
initiative will lead to the establishment of a large-scale cohort of 200,000 psychiatric
patients and control individuals. In addition to an initial cross-sectional assessment,
longitudinal follow-up of the cohort will be performed in order to obtain as much data as
possible concerning the course of the various psychiatric disorders. Within the context of
this study, the DGPPN aims to establish a national research network, which will both link
existing collections of biomaterials and empower centers with well characterized but small
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samples. Access to data and samples will be regulated in a transparent manner. Further goals
of the DGPPN cohort study are the development and implementation of standard operating
procedures and data policies to optimize the quality of biomaterials and data, and the
development of a core phenotypic assessment battery. Dr Anderson-Schmidt pointed out
that although the establishment of such standards is not an easy task, its feasibility has been
proven in countries in which large longitudinal cohort studies are already in progress, e.g.
the birth cohort studies in Denmark, Finland, and Norway. The DGPPN cohort has already
overcome the major initial challenges of such studies, such as data confidentiality, the
integration of data and samples from different sources, and the issue of maintaining the
independence of researchers who provide samples and data. Researchers can benefit from
the DGPPN cohort for a number of reasons. Firstly, integration of existing data will conform
to the highest data protection standards. Secondly, researchers will receive logistic and
financial support from the DGPPN in return for contributing to the cohort. Thirdly,
researchers will benefit from access to the cohort's large collection of samples and the
expertise of other centers. The data and samples will be available for all bona fida
psychiatric centers in Germany. During the discussion, the beneficial effect of linking
existing biomaterial collections was noted to be a major advantage of the DGPPN cohort
study, as individual collections are often too small to answer critical research questions.
Dr. Peter Falkai (University of Munich, Germany) described Brain Net Europe II (BNE), a
European-wide association of brainbanks which includes 20 European partners. BNE is an
initiative to promote brainbanking, and one of its main goals is to determine the effect of
pre- and post-mortem parameters on the preservation of DNA and RNA. BNE aims to set
gold standards for brainbanking and to provide training opportunities for researchers. To
date, BNE has collected more than 200 brains, including brains from patients with
Huntington's disease, Alzheimer's disease, and other psychiatric conditions. The most
critical ethical issue with respect to brainbanking is that of informed consent. Discussion is
required to clarify whether the consent of the relatives of the deceased to brain removal can
be considered adequate. During the discussion, clarification of who is responsible for the
samples and who will pay the running costs after the initial funding has ended was
requested. Peter Falkai pointed out that these are further issues which have yet to be
resolved.
The Norwegian registries, cohorts, and biobanks were described by Ted Reichborn. In
Norway, as well as in Denmark, Sweden, Finland and some other countries, the entire nation
is a cohort, as the registries and biobanks cover the majority of the population. In Norway,
everyone born since 1964 is included and assessed in 16 mandatory registries. In addition,
19 other clinical registries exist and the number is growing. Some of these registries are
linked with a biobank, and biomaterials from 500,000 individuals of all ages (10% of the
population) are available. The data derived from each of these registries and biobanks can be
linked with data stored in the other Norwegian registries. Since 2002, the Norwegian
government has permitted the storage of data without the individual informed consent of the
participant. These data are available for research, provided that they are handled in an
anonymized manner. Improved techniques present new challenges, e.g. the problem of
incidental or secondary findings during large sequencing efforts. He pointed out that this
particular issue still needs to be addressed and solved.
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Dr. Shawn Harmon, discussed the ethical issues surrounding brainbanking in the UK and
described existing legal solutions. At the time of writing, the UK has a total of 10
brainbanks. Each is based on a specific disease and was set up for a specific research
interest. The legal framework for brain banking in the UK is rudimentary and at present, no
specific biobanking regulation exists. The ethico-legal ambitions and objectives are to
conduct research in a manner which respects the dignity of the donors, which benefits
science, and which strengthens trust in scientists among the general population. Again, the
issue of incidental findings and the consequences of scientific uncertainty must be dealt
with.
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